0001213900-18-000698.txt : 20180119 0001213900-18-000698.hdr.sgml : 20180119 20180119160622 ACCESSION NUMBER: 0001213900-18-000698 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20171130 FILED AS OF DATE: 20180119 DATE AS OF CHANGE: 20180119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURA SYSTEMS INC CENTRAL INDEX KEY: 0000826253 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 954106894 STATE OF INCORPORATION: DE FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-17249 FILM NUMBER: 18537440 BUSINESS ADDRESS: STREET 1: 10541 ASHDALE STREET CITY: STANTON STATE: CA ZIP: 90680 BUSINESS PHONE: 3106435300 MAIL ADDRESS: STREET 1: 10541 ASHDALE STREET CITY: STANTON STATE: CA ZIP: 90680 10-Q 1 f10q1117_aurasystems.htm QUARTERLY REPORT

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended November 30, 2017

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from______________ to ______________

AURA SYSTEMS, INC.

(Exact name of Registrant as specified in its charter)

Delaware		95-4106894
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

10541 Ashdale St.

Stanton, CA 90680

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (310) 643-5300

Former name, former address and former fiscal year, if changed since last report:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: YES ☐ NO ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☐ NO ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐		Accelerated Filer ☐
Non-accelerated filer ☐		Smaller Reporting Company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the latest practicable date.

Class		Outstanding January 16, 2018
Common Stock, par value $0.0001 per share		126,608,391 shares

AURA SYSTEMS, INC.

INDEX

Index			Page No.

PART I. FINANCIAL INFORMATION			1

	ITEM 1.	Financial Statements (Unaudited)	1

		Balance Sheets as of November 30, 2017 and February 28, 2017	1

		Statements of Operations for the Three and Nine months Ended November 30, 2017 and 2016	2

		Statements of Cash Flows for the Three and Nine months Ended November 30, 2017 and 2016	3

		Notes to Financial Statements	4

	ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12

	ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	17

	ITEM 4.	Controls and Procedures	17

PART II. OTHER INFORMATION			18

	ITEM 1.	Legal Proceedings	18

	ITEM 1A.	Risk Factors	18

	ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18

	ITEM 3.	Defaults Upon Senior Securities	19

	ITEM 4.	Mine Safety Disclosures	19

	ITEM 5.	Other Information	19

	ITEM 6.	Exhibits	19

	SIGNATURES AND CERTIFICATIONS		20

ITEM 1. FINANCIAL STATEMENTS

AURA SYSTEMS, INC.
BALANCE SHEETS

(Unaudited)

	As of November 30,			As of February 28,
	2017			2017
ASSETS
Current assets:
Cash and cash equivalents	$	1,178,153		$	255,869
Other current assets		6,588			2,894
Total current assets		1,184,741			258,763

Deposits		3,500			3,500
Investment in Joint Venture		250,000			-

Total assets	$	1,438,241		$	262,263

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	4,827,902		$	4,943,559
Accrued expenses		7,082,010			5,939,251
Customer advances		670,751			641,751
Investor advance		1,000,000			-
Notes payable		3,413,058			4,776,938
Convertible note payable and accrued interest-related party, net of discount		3,304,445			2,920,172
Convertible notes payable, net of discount		6,629,763			4,177,283
Notes payable and accrued interest- related party		30,364,278			29,669,693

Total current liabilities		57,292,207			53,068,647

Total liabilities		57,292,207			53,068,647

Commitments and contingencies

Stockholders’ deficit:
Common stock, $0.0001 par value; 150,000,000 shares authorized at November 30 and February 28, 2017; 126,608,391 and 113,991,432 issued and outstanding at November 30 and February 28, 2017, respectively		12,661			11,399
Additional paid-in capital		412,666,277			410,499,597
Accumulated deficit		(468,532,904	)		(463,317,380	)

Total stockholders’ deficit		(55,853,966	)		(52,806,384	)

Total liabilities and stockholders’ deficit	$	1,438,241		$	262,263

The accompanying notes are an integral part of these financial statements.

AURA SYSTEMS, INC.

STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED NOVEMBER 30, 2017 AND 2016

(Unaudited)

	Three Months ended November 30,						Nine Months ended November 30,
	2017			2016			2017			2016

Net Revenues	$	-		$	-		$	-		$	-

Cost of goods sold		-			-			-			-

Gross Profit		-			-			-			-

Expenses
Engineering, research and development expenses		25,250			321			25,250			34,209
Selling, general and administrative expenses		822,616			470,725			1,753,419			1,319,146
Total costs and expenses		847,866			471,046			1,778,669			1,353,355

Loss from operations		(847,866	)		(471,046	)		(1,778,669	)		(1,353,355	)

Other (income) and expense
Interest expense, net		802,272			602,674			2,628,323			2,254,424
Gain on debt settlement		-			-			-			(70,288
Other (income) expense, net		11,396			-			808,532			(1,767	)
Total other (income) expense		813,668			602,674			3,436,855			2,182,369
Net Loss	$	(1,661,534	)	$	(1,073,720	)	$	(5,215,524	)	$	(3,535,724	)

Total basic and diluted loss per share	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.03	)
Weighted average shares used to compute basic and diluted income (loss) per share		126,608,391			113,951,432			125,324,765			113,916,887

*	Weighted average number of shares used to compute basic and diluted loss per share is the same since the effect of the dilutive securities is anti-dilutive.

See accompanying notes to these unaudited financial statements.

AURA SYSTEMS, INC.
STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED NOVEMBER 30, 2017 AND 2016
(Unaudited)

	Nine Months Ended November 30,
	2017			2016
Cash flow from operating activities:
Net Loss	$	(5,215,524	)	$	(3,535,724	)
Adjustments to reconcile Net loss to net cash used in operating activities		-			-
Amortization of debt discount		43,417			192,330
Gain on debt settlement		-			(70,288	)
FMV of warrants issued for services		177,737			-
Stock issued for services		990,205			-
(Increase) decrease in:
Accounts receivable		-			2,115
Other current assets and deposit		(3,694	)		100,101
Increase (decrease) in:
Accounts payable, customer deposit and accrued expenses		1,943,520			2,559,161
Net cash used in operations		(2,064,340	)		(752,305	)

Investing Activities:
Investment in Joint Venture		(250,000	)		-
Net cash used in investing activities		(250,000	)		-

Financing activities:
Issuance of common stock		1,000,000			-
Proceeds from notes payable-net		-			641,490
Proceeds from convertible notes payable		1,434,593			-
Payment to notes payable		(197,970	)		-
Proceeds from notes payable-related party, net		-			200,014
Investor Advance		1,000,000			-
Net cash provided by financing activities:		3,236,623			841,504

Net increase in cash & cash equivalents		922,284			89,199

Cash and cash equivalents at beginning of period		255,869			22,175

Cash and cash equivalents at end of period	$	1,178,153		$	111,374
Supplemental disclosures of cash flow information
Cash paid during the period for:
Interest	$	-		$	-
Income taxes		-			-

Unaudited supplemental disclosure of non-cash investing and financing activities:

During the nine months ended November 30, 2016, 950,000 shares of common stock were issued to settle a note payable balance of $150,000 plus accrued interest of $15,588.

See accompanying notes to these unaudited financial statements.

AURA SYSTEMS, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)

NOTE 1 – ACCOUNTING POLICIES

Accounting principles

In the opinion of management, the accompanying balance sheets and related interim statements of income and comprehensive income, and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended February 28, 2017 filed on September 18, 2017 with the U.S. Securities and Exchange Commission.

Estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Recently Issued Accounting Pronouncements

In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this Update supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this Update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU No. 2016-02 on our financial statements.

In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) that clarifies how to apply revenue recognition guidance related to whether an entity is a principal or an agent. ASU 2016-08 clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to the customer and provides additional guidance about how to apply the control principle when services are provided and when goods or services are combined with other goods or services. The effective date for ASU 2016-08 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. The Company has not yet determined the impact of ASU 2016-08 on its financial statements.

In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which provides further guidance on identifying performance obligations and improves the operability and understandability of licensing implementation guidance. The effective date for ASU 2016-10 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. In May 2016, the FASB issued ASU 2016-12 “Revenue from Contracts with Customers (Topic 606) - Narrow-Scope Improvements and Practical Expedients,” which amends the guidance on transition, collectability, non-cash consideration, and the presentation of sales and other similar taxes. ASU 2016-12 clarifies that, for a contract to be considered completed at transition, all (or substantially all) of the revenue must have been recognized under legacy GAAP. In addition, ASU 2016-12 clarifies how an entity should evaluate the collectability threshold and when an entity can recognize nonrefundable consideration received as revenue if an arrangement does not meet the standard’s contract criteria. The standard allows for both retrospective and modified retrospective methods of adoption. The Company has not yet determined the impact of ASU 2016-10 on its financial statements.

In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Statements,” which requires companies to measure credit losses utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2019 (fiscal year 2021 for the Company). The Company has not yet determined the potential effects of the adoption of ASU 2016-13 on its Financial Statements.

In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which aims to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. ASU 2016-15 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017 (fiscal year 2019 for the Company). The Company has not yet determined the potential effects of the adoption of ASU 2016-15 on its Financial Statements.

Reclassifications

Certain reclassifications have been made to the comparative financial statements to conform to the current period presentation.

NOTE 2 – GOING CONCERN

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. During the nine months ended November 30, 2017 and November 30, 2016, the Company incurred losses of $5,215,524 and $3,535,724, respectively and had negative cash flows from operating activities of $2,064,340 and $752,305, respectively.

If the Company is unable to generate profits and is unable to continue to obtain financing for its working capital requirements, it may have to curtail its business sharply or cease business altogether.

Substantial additional capital resources will be required to fund continuing expenditures related to our research, development, manufacturing and business development activities. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis, to retain its current financing, to obtain additional financing, and ultimately to attain profitability.

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that could result from the outcome of this uncertainty.

During the next twelve months we intend to restart operations of our AuraGen/VIPER business both domestically and internationally. At the next shareholders meeting the shareholders will vote for an entire new slate of five board candidates. The new board when elected will hire a new management team. In addition we plan to acquire a new facility of approximately 45,000 square feet for operations, as well as, rebuild the engineering QA and sales teams to support the operation. We anticipate being able to fund these additions in the upcoming fiscal year.

NOTE 3 – NOTES PAYABLE

Notes payable consisted of the following:

	November 30, 2017		February 28, 2017

Demand notes payable, at 10% and 16%	$	3,413,058	$	3,782,238
Convertible Promissory Note dated August 10, 2012, due August 10, 2017, convertible into shares of our common stock at a price of $0.76 per share. The note carries an interest rate of 7% with interest only payments due on the 10^th of each month with the principal payment due on the maturity date. To-date, the Company has not made any interest payments as set forth in this note.		1,000,000		972,632
Convertible Promissory Note dated October 2, 2012, due October 2, 2017, convertible into shares of our common stock at a price of $0.76 per share. The note carries an interest rate of 7% with interest only payments due on the 2^nd of each month with the principal payment due on the maturity date. To-date, the Company has not made any interest payments as set forth in this note.		500,000		483,951
Senior secured convertible notes dated May 7, 2013, due May 7, 2014, convertible into shares of our common stock at a price of $0.75 per share. The note was not repaid.		2,395,700		2,395,700
Senior secured convertible notes dated June 20, 2013, due June 20, 2014, convertible into shares of our common stock at a price of $0.50 per share. The note was not repaid.		325,000		325,000
Convertible notes dated April 2016 thru November 2017. The notes carry an interest rate of 5% and might be converted into shares of Company’s common stock if the shareholders approve a 1:7’ reverse stock split.		2,409,063		994,700

		10,042,821		8,954,221

Less: Current portion	$	10,042,821	$	8,954,221

Long-term portion	$	-	$	-

CONVERTIBLE DEBT

On May 7, 2013, the Company transferred 4 notes payable with a total principal value of $1,000,000 together with accrued interest, and consulting fees to a senior secured convertible note with a principal value of $1,087,000 and warrants to Kenmont Capital Partners. This new note has a 1-year maturity date and is convertible into shares of common stock at the conversion price of $0.75 per share. The warrants entitle the holder to acquire 1,449,333 shares of common stock, have an initial exercise price of $0.75 per share, and have a 7-year term. The Company recorded $342,020 as a discount, which will be amortized over the life of the note.

On May 7, 2013, the Company transferred 2 note payables with a total principal value of $550,000 together with accrued interest to a senior secured convertible note with a principal value of $558,700 and warrants to LPD Investments, Ltd. This new note has a 1-year maturity date and is convertible into shares of common stock at the conversion price of $0.75 per share. The warrants entitle the holder to acquire 744,933 shares of common stock, have an initial exercise price of $0.75 per share, and have a 7-year term. The Company recorded $175,793 as a discount, which will be amortized over the life of the note.

On May 7, 2013, the Company entered into an agreement with an individual for the sale of a secured convertible note payable in the original principal amount of $750,000 and warrants. This note has a 1-year maturity date and is convertible into shares of common stock at the conversion price of $0.75 per share. The warrants entitle the holder to acquire 1,000,000 shares of common stock, have an initial exercise price of $0.75 per share, and have a 7-year term. The Company recorded $235,985 as a discount, which will be amortized over the life of the note.

On June 20, 2013, the Company entered into an agreement with four individuals for the sale of secured convertible notes payable in the original amount of $325,000 and warrants. These Notes have a 1-year maturity date and are convertible into shares of common stock at the conversion price of $0.50 per share. The warrants entitle the holders to acquire 433,334 shares of common stock, have an initial exercise price of $0.75 per share, and have a 7-year term. The Company recorded $63,622 as a discount, which will be amortized over the life of the notes.

On August 19, 2013, the Company entered into an agreement with a member of its Board of Directors for the sale of $2,500,000 of unsecured convertible notes payable and warrants. These notes carry a base interest rate of 9.5%, have a 4-year maturity date and are convertible into shares of common stock at the conversion price of $0.50 per share. The warrants entitle the holder to acquire 5,000,000 shares of common stock, have an initial exercise price of $0.75 per share and have a 7-year term. The Company recorded $667,118 as a discount, which will be amortized over the life of the note.

All convertible notes payable are due within twelve months or have not been paid when originally due.

CONVERTIBLE PROMISSORY NOTES

At February 28, 2013, the three other unsecured convertible promissory notes payable amounted to $1,447,938, net of discounts of $402,063. These convertible notes bear interest at 7% per annum, and are convertible into common stock of the Company at $0.76 per share (as well as variable conversion rates as described below). These notes are due on August 10, 2017, October 2, 2017, and January 4, 2013. On May 7, 2013, the note due on January 4, 2013 was converted into a portion of the note due June 15, 2013, which carries an interest rate of 12%.

During the quarter ended November 30, 2017, the company entered into agreements with various individuals for the aggregate sale of $615,953 of unsecured convertible notes and warrants. Pursuant to the terms of these notes, such notes will be converted in their entirety into shares of common stock of the Company at the conversion price of $0.07 per share upon stockholder approval of a 1-for-7 reverse stock split. The warrants entitle the holders to acquire up to an aggregate of 132,000 shares of common stock and have an initial exercise price of $0.20 per share which will be adjusted to $1.40 per share upon stockholder approval of a 1-for-7 reverse stock split. The stockholders approved the reverse stock split at the Company’s stockholder meeting on January 11, 2018.

7% Convertible Promissory Notes:

On August 10, 2012 the Company entered into an agreement with an individual for the sale of an unsecured convertible promissory note in the original principal amount of $1,000,000. This convertible promissory note is due and payable on August 10, 2017 and bears an interest rate is 7% per annum. Interest on the unpaid principal amount of this note is payable monthly in arrears, on the tenth day of each calendar month, commencing September 10, 2012. Interest is computed on the actual number of days elapsed over a 360-day year. The Holder has the right to convert any outstanding and unpaid principal portion of this convertible promissory note into shares of common stock. The company recorded $310,723 as a debt discount, which will be amortized over the life of the note.

On October 2, 2012 the Company entered into an agreement with an individual for the sale of an unsecured convertible promissory note in the original principal amount of $500,000. This convertible promissory note is due and payable on October 2, 2017 and bears an interest rate is 7% per annum. Interest on the unpaid principal amount of this note is payable monthly in arrears on the second day of each calendar month, commencing November 2, 2012. Interest is computed on the actual number of days elapsed over a 360-day year. The Holder has the right to convert any outstanding and unpaid principal portion of this convertible promissory note into shares of common stock. The company recorded $137,583 as a debt discount, which will be amortized over the life of the note.

On January 30, 2017 the Company entered into an agreement entitled First Amendment to Transaction Documents with five of seven of its secured creditors. These creditors hold a security interest in all of the Company’s assets except for its patents and other intellectual properties. The original agreement dated May 7, 2013 provided that if the holders of at least 75% of the stock issuable upon conversion of the convertible notes votes to amend the agreement, then such amendments will be binding on all the secured creditors. The five secured creditors signing the amendment total in excess of 95% of the issuable stock upon conversion and, therefore the agreement is binding on all seven of the secured creditors. The amended agreement provides that all accrued and unpaid interest will be added to the principal amount, the amended notes bear interest at the rate of 0% through the sooner of (i) January 15, 2018 or (ii) the fifth business day following a stockholder meeting and 5% per annum thereafter, subject to reduction to comply with applicable law, and mature in 60 months from the effective date of a proposed 1-for-7 reverse stock split (which may only be effected if approved by the stockholders at the next annual meeting of stockholders). Upon certain financings, within five business days following stockholder approval of a 1-for-7 reverse stock split, the Company is obligated to make a payment to the holders of the amended notes in the amount of 20% of the outstanding secured notes. Upon the effectiveness of a proposed 1-for-7 reverse stock split, the remaining 80% balance of the amended notes is converted into shares of the Company’s common stock. After the effectiveness of a proposed 1-for-7 reverse stock split, the secured note holders may voluntarily convert the unpaid principal and interest thereon into the Company’s common stock at the conversion price of $1.40 per share.

On February 21, 2017 the Company entered into debt refinancing agreements with several debt holders relating to aggregate unsecured debt totaling $2,237,456 including interest of $489,466. This refinancing agreement waives any past events of default and provides for new five-year convertible notes which bear no interest through the sooner of (i) January 15, 2018 or (ii) the fifth business day following a stockholder meeting and 5% per annum thereafter. Upon stockholder approval of a 1-for-7 reverse stock split, these notes will be converted into a total of 1,164,555 shares of common stock. The notes also provide various default provisions.

The stockholders approved the reverse split at the Company’s stockholder meeting on January 11, 2018.

NOTE 4 – ACCRUED EXPENSES

Accrued expenses consisted of the following:

	November 30, 2017		February 28, 2017

Accrued payroll and related expenses	$	2,781,312	$	3,099,842
Accrued rent		202,036		202,036
Accrued interest		4,073,662		2,562,375
Other		25,000		75,000
Total	$	7,082,010	$	5,939,252

Accrued payroll and related expenses consists of salaries and vacation time accrued but not paid to employees due to our lack of financial resources.

NOTE 5 – SHAREHOLDERS’ EQUITY

Common Stock

During the nine months ended November 30, 2017, we issued 5,000,000 shares of common stock for $1,000,000 in conjunction with our Chinese Joint Venture, we issued 5,116,959 shares of common stock valued at $665,204 as part of a settlement agreement, and we issued 2,500,000 shares of common stock valued at $325,000 in connection with a consulting agreement.

During the nine months ended November 30, 2016, we issued 950,000 shares of common stock as a settlement for a note payable balance of $150,000 plus accrued interest of $15,288.

Employee Stock Options

During the nine months ended November 30, 2017, there were no stock options granted to employees.

In September, 2006, our Board of Directors adopted the 2006 Employee Stock Option Plan. Activity in this plan is as follows:

	2006 Plan
	Weighted- Average Exercise Price		Aggregate Intrinsic Value		Number of Options
Outstanding, February 28, 2017		$0.75-$1.00	$	0.00		7,224,000
Cancelled		-		-		-
Granted		-		-		-
Outstanding, November 30, 2017		$0.75-$1.00	$	0.00		7,224,000

The exercise prices for the options outstanding at November 30, 2017, and information relating to these options is as follows:

Options Outstanding

Exercisable Options

Range of
Exercise
Price

Number

Weighted
Average
Remaining
Life

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life

Number

Weighted
Average
Exercise
Price

$0.75-$1.00

7,224,000

2.25 years

0.79

2.25 years

7,224,000

0.79

Warrants

Activity in issued and outstanding warrants is as follows:

	Number of Shares		Exercise Prices
Outstanding, February 28, 2017		26,454,021		$0.10-$1.00
Granted		1,400,000	$	.20
Exercised		-		-
Cancelled		406,941		1.00
Outstanding, November 30, 2017		27,447,080		$0.10-$1.00

The exercise prices for the warrants outstanding at November 30, 2017, and information relating to these warrants is as follows:

Range of Exercise Prices	Stock Warrants Outstanding		Stock Warrants Exercisable		Weighted- Average Remaining Contractual Life		Weighted- Average Exercise Price of Warrants Outstanding		Weighted- Average Exercise Price of Warrants Exercisable		Intrinsic Value
$0.20		1,400,000		1,400,000		51 months	$	0.20	$	0.20	$	0.00
$0.10-$0.75		18,381,012		18,381,012		41 months	$	0.55	$	0.41	$	0.00
$0.75		1,082,734		1,082,734		39 months	$	0.75	$	0.75	$	0.00
$0.75		1,000,000		1,000,000		29 months	$	0.75	$	0.75	$	0.00
$0.75-$1.00		5,583,334		5,583,334		26 months	$	0.75	$	0.75	$	0.00

		27,447,080		27,447,080

NOTE 5 – RELATED PARTIES TRANSACTIONS

On January 24, 2017 the Company entered into a Debt Refinancing Agreement with Mr. Warren Breslow, who served as a Director of the Company from 2006 to 2017. Mr. Breslow resigned his position on our board in March 2017. Pursuant to this agreement, both Mr. Breslow and the Company acknowledged that total debt owed to Mr. Breslow and his affiliates was $23,872,614 including $8,890,574 of accrued interest. Mr. Breslow agreed to cancel and forgive all interest due, waive any past events of default and sign a new, five-year unsecured convertible note, in the amount of $14,982,041. This new note bears no interest through the sooner of (i) January 15, 2018 or (ii) the fifth business day following a shareholder meeting, and 5% per annum thereafter. This new note also provides various default provisions. The refinancing agreement further provides that $11,982,041 of Mr. Breslow’s new note will be converted into 7,403,705 shares of common stock upon stockholder approval of a 1-for-7 reverse stock split within eighteen months of entering into that agreement; the remaining balance may thereafter be converted at any time. In the absence of stockholder approval of a 1-for-7 reverse stock split within eighteen months, the refinancing agreement will become null and void. The Company has elected to continue to accrue interest on this agreement until such time as the 1-for-7 reverse stock split has been approved. The stockholders approved the reverse split at the Company’s stockholder meeting on January 11, 2018.

At November 30, 2017, the balance in Notes Payable and accrued interest-related party, current, includes $14,982,041 of unsecured notes payable plus accrued interest of $10,010,053 to Mr. Breslow, a member of our Board of Directors, payable on demand, bearing interest at a rate of 10% per annum. The balance was $14,982,041 plus accrued interest of $8,890,574 as of February 28, 2017. During the periods ended November 30, 2017 and November 30, 2016, interest amounting to $1,119,480 and $993,647 respectively, was incurred on these notes. Related Parties Transactions also includes $82,000 of unsecured notes payable plus accrued interest of $35,268 and $29,141 to our CEO pursuant to a demand note entered into on April 5, 2014 and an unsecured note payable to Mr. Kopple, another member of our Board of Directors in the total amount of $3,029,930 and $3,587,322 plus accrued interest of $2,040,533 and $2,098,616 pursuant to 10% demand note payable as of November 30, 2017 and February 28, 2017, respectively. At November 30, 2017, the balance in Convertible note payable and accrued interest-related party, long term, includes $2,000,000 of secured convertible notes payable plus accrued interest of $1,145,258 to Mr. Kopple.

NOTE 7 – COMMITMENTS

Leases

Our facilities consist of approximately 20,000 rented square feet in Stanton, California. The Stanton facility is currently being used for small quantity assembly and testing using components that are produced by various suppliers as well as for general offices, engineering and warehousing. The rent for the Stanton facility is $10,000 per month. The facility is not sufficient for our near term anticipated needs and the Company is actively looking for a new facility. The Company arrangements for the Stanton facility are on a month per month rent.

Joint Venture

On January 27, 2017, the Company entered into a joint venture (JV) agreement with a Chinese company to manufacture market and distribute certain mobile power products based on Aura’s patented technology solely for the Peoples Republic of China territories. The JV is owned 49% by the Company and 51% by the Chinese company. The Company has contributed $250,000 and a license to specific technology and the Chinese company is required to contribute $9,750,000. In addition, the Chinese company will invest $2,000,000 in Aura at $0.20 per share for a total of 10,000,000 shares of common stock. Additionally, the Chinese company will purchase a minimum of $1,250,000 of product supported by letters of credit for distribution until the joint venture factory is built, equipped, and staffed. In order to assure proper training of joint venture personnel, Aura has also committed to supply instructional personnel for six months at no cost other than reimbursement for travel, room and board. The agreement was subject to the approval of the Chinese Government which was received in April, 2017.

NOTE 8 – SUBSEQUENT EVENTS:

The Company is presently engaged in a dispute with one of its directors, Robert Kopple, relating to approximately $5.4 million and approximately 22 million warrants which Mr. Kopple claims to be owed to him and his affiliates by the Company. In July 2017, Mr. Kopple filed suit against the Company as well as against current Directors Mr. Gagerman and Mr. Diaz-Verson together with former Directors Mr. Breslow and Mr. Howsmon in connection with these allegations. The Company believes that it has valid defenses in these matters and intends to vigorously defend against these claims.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

This Report contains forward-looking statements within the meaning of the federal securities laws. Statements other than statements of historical fact included in this Report, including the statements under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” regarding future events or prospects are forward-looking statements. The words “approximates,” “believes,” “forecasts,” “expects,” “anticipates,” “estimates,” “intends,” “plans” “would,” “could,” “should,” “seek,” “may,” or other similar expressions in this Report, as well as other statements regarding matters that are not historical fact, constitute forward-looking statements. We caution investors that any forward-looking statements presented in this Report are based on the beliefs of, assumptions made by, and information currently available to, us. Such statements are based on assumptions and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond our control or ability to predict. Although we believe that our assumptions are reasonable, they are not guarantees of future performance and some will inevitably prove to be incorrect. As a result, our actual future results may differ from our expectations, and those differences may be material. Accordingly, investors should use caution in relying on forward-looking statements to anticipate future results or trends.

Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements include the following:

●

Our ability to generate positive cash flow from operations;

●

Our ability to obtain additional financing to fund our operations;

●

The impact of economic, political and market conditions on us and our customers;

●

The impact of unfavorable results of legal proceedings;

●

Our exposure to potential liability arising from possible errors and omissions, breach of fiduciary duty, breach of duty of care, waste of corporate assets and/or similar claims that may be asserted against us;

●

Our ability to compete effectively against competitors offering different technologies;

●

Our business development and operating development;

●

Our expectations of growth in demand for our products; and

●

Other risks described under the heading “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q and those risks discussed in our other filings with the Securities and Exchange Commission, including those risks discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended February 28, 2017 (as the same may be updated from time to time in subsequent quarterly reports), which discussion is incorporated herein by this reference.

We do not intend to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except to the extent required by law. You should interpret all subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf as being expressly qualified by the cautionary statements in this Report. As a result, you should not place undue reliance on these forward-looking statements.

Overview

Our business is based on the exploitation of our patented mobile power solution known as the AuraGen for commercial and industrial applications and the VIPER for military applications. Our business model consists of three major components: (i) sales and marketing, (ii) engineering, and (iii) customer service and support.

(i) Our sales and marketing approach is composed of direct sales in North America and the use of agents, distributors and joint ventures for sales internationally. In North America, our primary focus is in (a) transport refrigeration, and (b) U.S. Military applications.

(ii) The second component of our business model is focused on the engineering support for the sales activities described above. The engineering support consists of the introduction of new features for our AuraGen/VIPER solution such as higher power, different voltages, three phase options, shore power systems, higher current solutions as well as interface kits for different platforms.

(iii) The third component of our business model is customer service. In fiscal 2018, we expect to rehire several previously trained field engineers to support our product in North America. In addition, we are working closely with our Chinese Joint Venture partner to train their staff to support our products overseas.

During the first half of fiscal 2016, the Company significantly reduced operations due to lack of financial resources. During the second half of fiscal 2016 the Company’s operations were disrupted when the Company was forced to move from its facilities in Redondo Beach, California to a smaller facility in Stanton, California. Operations during the second half of fiscal 2016 were sporadic. During fiscal 2017, the Company suspended its engineering, manufacturing, sales, and marketing activities to focus on renegotiating numerous financial obligations.

The Company has been successful in restructuring its secured debt and has reached an agreement with its secured creditors whereby all defaults and penalties have been waived and 80% of the secured debt will be converted into shares of the Company’s common stock as soon as the Company holds an annual meeting of stockholders to elect a new board of directors. The balance (the remaining 20%), is to be paid to the secured creditors in cash within five business days following stockholder approval of a 1-for-7 reverse stock split provided that certain financings milestones have been reached by the Company. Upon conversion, the converting secured creditors will receive approximately 3.9 million new common shares in exchange for approximately $5.73 million of converting debt.

The Company has also been successful in restructuring approximately $27.5 million of unsecured debt. Various unsecured creditors have agreed to waive all defaults and penalties, to forgive an aggregate of approximately $9.3 million in debt, and convert an aggregate of approximately $15.2 million of unsecured debt into approximately 10.2 million common shares. As of the date of this filing, Robert Kopple, the Company’s Vice Chairman of the Board, is the only significant unsecured note holder that has not agreed to restructure his debt. Mr. Kopple claims to be owed approximately $5.4 million on terms significantly preferable to other similarly-situated unsecured creditors. Mr. Kopple has not accepted the Company’s offer to restructure this debt to-date.

Our financial statements included in this report have been prepared on the assumption that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, as a result of our losses from operations, there is substantial doubt about our ability to continue as a going concern. Our independent auditors, in their report on the Company’s financial statements for the year ended February 28, 2017 expressed substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classification of liabilities that may result from our possible inability to continue as a going concern.

Our ability to continue as a going concern is dependent upon the successful achievement of profitable operations, and the ability to generate sufficient cash from operations and obtain financing resources to meet our obligations. There is no assurance that such efforts will be successful.

Our current level of sales reflects our efforts to introduce a new product into the marketplace. Until recently, many purchases of the product were for evaluation purposes. Recently we started to receive repeat orders for larger quantities as different organizations are integrating our products into their vehicles. We seek to achieve profitable operations by obtaining market acceptance of the AuraGen^® as a competitive - if not superior - product providing mobile power anywhere anytime. There can be no assurance that this success will be achieved.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements requires management to make estimates and disclosures on the date of the financial statements. On an on-going basis, we evaluate our estimates, including, but not limited to, those related to revenue recognition. We use authoritative pronouncements, historical experience and other assumptions as the basis for making judgments. Actual results could differ from those estimates. We believe that the following critical accounting policies affect our more significant judgments and estimates in the preparation of our consolidated financial statements.

Revenue Recognition

We are required to make judgments based on historical experience and future expectations, as to the reliability of shipments made to our customers. These judgments are required to assess the propriety of the recognition of revenue based on Staff Accounting Bulletin (“SAB”) No. 101, “Revenue Recognition,” and related guidance. Because sales are currently in limited volume and many sales are for evaluative purposes, we have not booked a general reserve for returns. We will consider an appropriate level of reserve for product returns when our sales increase to commercial levels.

Inventory Valuation and Classification

Inventories consist primarily of components and completed units for our AuraGen^® product. Inventories are valued at the lower of cost (first-in, first-out) or market. Provision is made for estimated amounts of current inventories that will ultimately become obsolete due to changes in the product itself or vehicle engine types that go out of production. Management believes that existing inventories can, and will, be sold in the future without significant costs to upgrade it to current models and that the valuation of the inventories accurately reflects the realizable values of these assets. The AuraGen^® product being sold currently is not technologically different from those in current use. Existing finished goods inventories can be upgraded to the current model with only a small amount of materials and manpower. We make these assessments based on the following factors: i) existing orders, ii) age of the inventory, iii) historical experience and iv) our expectations as to future sales. If expected sales volumes do not materialize, there would be a material impact on our financial statements.

Valuation of Long-Lived Assets

Long-lived assets, consisting primarily of property and equipment, and patents and trademarks, comprise a portion of our total assets. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying values August not be recoverable. Recoverability of assets is measured by a comparison of the carrying value of an asset to the future net cash flows expected to be generated by those assets. Net cash flows are estimated based on expectations as to the realize-ability of the asset. Factors that could trigger a review include significant changes in the manner of an asset’s use or our overall strategy.

Specific asset categories are treated as follows:

Accounts Receivable: We record an allowance for doubtful accounts based on our expectation of collect-ability of current and past due accounts receivable.

Property, Plant and Equipment: We depreciate our property and equipment over various useful lives ranging from five to ten years. Adjustments are made as warranted when market conditions and values indicate that the current value of an asset is less than its net book value.

When we determine that an asset is impaired, we measure any such impairment by discounting an asset’s realizable value to the present using a discount rate appropriate to the perceived risk in realizing such value. When we determine that an impaired asset has no foreseeable realizable value, we write such asset down to zero.

Results of Operations

Nine months ended November 30, 2017 compared to nine months ended November 30, 2016

Net revenues were $0 for the nine months ended November 30, 2017 (the “Nine Months FY 2018”) and the nine months ended November 30, 2016 (the “Nine Months FY 2017”). The Company has virtually ceased operations due to a lack of adequate financial resources to conduct operations.

Cost of goods were $0 in the Nine Months FY 2018 and the Nine Months FY 2017 as a result of the virtual cessation of operations as noted above.

Engineering, research and development expenses decreased $8,959 (26%) to $25,250 in the Nine Months FY 2018 from $34,209 in the Nine Months FY 2017. All the expense in the current year period is due to the Company redesigning the ECU for the Auragen system.

Selling, general and administrative expense increased $434,273(33%) to $1,753,419 in the Nine Months FY 2018 from $1,319,146 in the Nine Months FY 2017. The increase is primarily attributable to an increase in legal expenses of approximately $445,000.

Net interest expense in the Nine Months FY 2018 increased $373,899 (17%) to $2,628,323 from $2,254,424 in the Nine Months FY 2017.

Our net loss for the Nine Months FY 2018 increased $1,679,800 to $5,215,524 from $3,535,724 in the Nine Months FY 2017.

Three months ended November 30, 2017 compared to three months ended November 30, 2016

Net revenues were $0 for the three months ended November 30, 2017 (the “Third Quarter FY 2018”) and the three months ended November 30, 2016 (the “Third Quarter FY 2017”). The Company has virtually ceased operations due to a lack of funding.

Cost of goods were $0 in the Third Quarter FY 2018 and the Third Quarter FY 2017 as a result of the virtual cessation of operations as noted above.

Engineering, research and development expenses increased $24,929 to $25,250 in the Third Quarter FY 2018 from $321 in the Third Quarter FY 2017. All the expense in the current year period is due to the Company redesigning the ECU for the Auragen system.

Selling, general and administrative expense increased $351,891 (75%) to $822,616 in the Third Quarter FY 2018 from $470,725 in the Third Quarter FY 2017.

Net interest expense in the Third Quarter FY 2018 increased $199,598 (33%) to $802,272 from $602,674 in the Third Quarter FY 2017.

Our net loss for the Third Quarter FY 2018 increased $587,814 to $1,661,534 from $1,073,720 in the Third Quarter FY 2017.

Liquidity and Capital Resources

We had cash of approximately $1,178,000 and $256,000 as of November 30, 2017, and February 28, 2017, respectively. We had a working capital deficit at November 30, 2017, and February 28, 2017 of $56,107,466 and $52,809,884, respectively. The working capital deficit includes notes payable and accrued interest to related parties of $30,364,278 and $29,669,693 as of November 30 and February 28, 2017, respectively.

Net cash used in operations for the nine months ended November 30, 2017, was $3,123,197, an increase of $2,370,892 from the comparable period in the prior fiscal year. Net cash used in investing activities consists of our investment of $250,000 in our Chinese joint venture. Net cash provided by financing activities during the nine months ended November 30, 2017, was $4,295,481, resulting from net proceeds from notes payable of $2,295,481, the issuance of common stock for $1,000,000, and an investor advance of $1,000,000.

There were no acquisitions of property and equipment in the Nine months FY 2018 or the Nine months FY 2017.

Accrued expenses as of November 30, 2017 increased $1,000,319 to $6,939,570 from $5,939,251 as of February 28, 2017. Approximately $1,335,000 of accrued expenses is salaries accrued but unpaid to certain employees and ex-employees due to a lack of resources, and approximately $500,000 is accrued but unused vacation time earned by employees.

Net proceeds from the issuance of debt totaled $2,295,481 in the nine months FY 2018, compared with $841,504 in the nine months FY 2017. As of November 30, 2017, the total amount owing a board member is $14,982,040 plus accrued interest of approximately $10,010,053. We also owe another Board member a total of $5,288,081 plus accrued interest of approximately $3,217,903. If the Board members were to demand repayment, we do not currently have the resources to make the payments.

The Company had a deficit of $55,853,966 in shareholders’ equity as of November 30, 2017, compared to $52,806,384 as of February 28, 2017.

Since 2002 substantially all of our revenues from operations have been derived from sales of the AuraGen^®. The cash flow generated from our operations to date has not been sufficient to fund our working capital needs, and we cannot predict when operating cash flow will be sufficient to fund working capital needs.

In the past, in order to maintain liquidity we have relied upon external sources of financing, principally equity financing and private indebtedness. We have no bank line of credit and require additional debt or equity financing to fund ongoing operations. The issuance of additional shares of equity in connection with any such financing could dilute the interests of our existing stockholders, and such dilution could be substantial. If we cannot raise needed funds, we would also be forced to make further substantial reductions in our operating expenses, which could adversely affect our ability to implement our current business plan and ultimately our viability as a company.

Capital Transactions

During the nine months ended November 30, 2016, we issued 950,000 shares of common stock to settle a note payable balance of $150,000 plus accrued interest of $15,588.

Inventories

Inventories consist primarily of components and completed units of the Company’s AuraGen^® product.

Early in our AuraGen^® program, we determined it was most cost-effective to outsource production of components and subassemblies to volume-oriented manufacturers, rather than produce these parts in house. As a result of this decision, and based on then anticipated sales, we purchased, prior to fiscal 2001, a substantial inventory of components at volume prices. Since sales did not meet such expectations, we have been selling product from this inventory for several years.

Most of our inventory consists of a variety of (i) metallic, mechanical components, and (ii) electrical components including metallic chassis to hold the assembled electrical systems. The vast majority of mechanical components are not aged and most of the electrical components are also not aged. The components that are aged are related to the prime mover/Generator interface that may not be in demand any longer.

In the past we have offered and ship three different basic models of systems; (i) a 5 kW based systems, (ii) an 8.5 kW based system and (iii) a 16 kW based systems (two 8.5 kW systems configured in tandem back-to-back). Each of these systems can be configured with different options such as 110 VAC only, 220 VAC only, 24 VDC only, 12 VDC only and AC/DC combinations of the same or different voltages. In addition, the system can be configured with single phase, split phase or three-phase output.

A number of the mechanical components are common to all three of the above configurations, while others are very specific. For example, the stators and rotors for the 5 kW systems are different from the 8.5 kW systems, but the housings are the same. Similarly, the electrical components consist of some parts that are geared for a specific configuration while others are generic and can be used for all of the configurations. The electrical chassis are also interchangeable between the 5 kW and 8.5 kW configurations. Due to the nature and mix of the product being sold, frequently, the 5 kW electrical systems are upgraded to 8.5 kW systems by replacing some components.

From the above description one can understand that the inventory consists of numerous components and subassemblies but not finished systems; therefore, each system that is sold and shipped to a customer is built from some components that are in inventory and others that need to be purchased to be able to configure the required system.

8.5 kW systems represent the majority of product previously shipped. These systems are built by using existing inventory subassemblies and parts, including some that can be used for both 5 kW and 8.5 kW systems, and additional parts that are purchased to provide the required configuration. Typically, such systems are built using approximately 20 to 25 percent of existing inventory and approximately 75% of additional parts that are purchased.

However, most of the systems sold to the Korean military consist of 5 kW systems. They have been purchasing approximately 100 systems per year and have indicated to us that they will continue to do so for the next five years. To date we have shipped over 500 such systems (in this case 100% of the rotors and stators are used from existing inventory and over 50% of the electrical parts are also from inventory).

In addition to the above, we have encountered demand for different and unique configurations that require the purchase of additional parts.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide disclosure under this Item 3.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the specified time periods. For the last 3 fiscal years, these control and procedures broke down due to insufficient capital to maintain such controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to its management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. As of the end of the period covered by this report, the Company’s management evaluated, with the participation of the Company’s Chief Executive Officer and acting Chief Financial Officer, the effectiveness of the Company’s disclosure controls and procedures. Based on the evaluation, the Company’s Chief Executive Officer and acting Chief Financial Officer concluded that these controls and procedures were ineffective for the last 3 fiscal years in ensuring that information requiring disclosure is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during our fiscal quarter ended November 30, 2017, which have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings

We are subject to the legal proceedings and claims discussed below as well as certain other legal proceedings and claims that have not been fully resolved and that have arisen in the ordinary course of business. Our management evaluates our exposure to these claims and proceedings individually and in the aggregate and evaluates potential losses on such litigation if the amount of the loss is estimable and the loss is probable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company for amounts in excess of management’s expectations, the Company’s consolidated financial statements for that reporting period could be materially adversely affected. The Company settled certain matters subsequent to year end that did not individually or in the aggregate have a material impact on the Company’s financial condition or operating results.

In 2016, the Company was sued by a former employee for a work-related injury. The plaintiff is seeking $45,000. The Company has made the plaintiff a settlement offer which, as of the date of this filing, has not been accepted.

In November 2016, the Company was sued by a former customer for approximately $111,712 relating to an alleged failure by the Company to partially deliver against an advanced payment. In connection with its claims, the plaintiff has asserted that by virtue of the Company’s failure to fully deliver upon the contracted order, the plaintiff has obtained a perpetual worldwide license to utilize the Company’s actuator technology. The Company disputes the plaintiff’s claims and believes that it holds various claims against the plaintiff. In April 2017, the plaintiff’s action was involuntarily dismissed by the court although plaintiff sought to have the dismissal set aside on the grounds of attorney error. In June 2017, the court granted plaintiff’s motion and the Company intends to oppose this action and file a counterclaim.

Subsequent to year end, the Company’s former COO has been awarded approximately $238,000 in accrued salary and related charges by the California labor board. The Company believes that this award does not reflect the amount owed which is significantly lower and is exploring all its options and available remedies and is working toward an offer to settle this matter.

The Company and the Company’s Chief Executive Officer, Melvin Gagerman, are among several defendants named in a lawsuit filed by two secured creditors demanding repayment of loans totaling $125,000 plus accrued interest and exemplary damages. In January 2017, the Company entered into an agreement with all secured creditors other than the two plaintiffs. However, because secured creditors holding in excess of 97% of the issuable stock upon conversion have executed the agreement, the agreement is binding on all of the secured creditors, including the two plaintiffs. That agreement, among other provisions, waives all past events of default. It is the Company’s position that the two plaintiffs are not entitled to any payment or other relief at this time and therefore that they have no valid claim against the Company or Mr. Gagerman. In March 2017, plaintiffs moved for partial summary adjudication against the Company and Mr. Gagerman; however, the Court denied plaintiff’s motion. Thereafter, the Court sustained demurrers by Mr. Gagerman and the Company but granted plaintiffs leave to amend. In response to the plaintiffs’ second amended complaint, both the Company and Mr. Gagerman intend to further demurrer seeking dismissal of this action.

In June 2015, the landlord of the Company’s primary facility in Redondo Beach, California initiated litigation against us seeking to terminate the Company’s lease and require the Company to vacate the premises prior to the scheduled lease end. As a result of that litigation, the Company was forced to vacate its primary facility and relocate to its present facility in Stanton, California. To date, no action seeking damages or any other amount has been filed against the Company by the landlord, nor does the Company believe it has any further liability to the landlord.

ITEM 1A. Risk Factors.

In addition to the other information set forth in this report, you should carefully consider the risk factors disclosed in Item 1A, “Risk Factors,” of the Company’s annual report on Form 10-K for the year ended February 28, 2017.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended November 30, 2017, we did not issue any shares of common stock.

All of the sales of unregistered securities are believed to be exempt from registration pursuant to Section 4(2) of the Securities Act of 1933 as these offerings were a private placement to a limited number of qualified investors without public solicitation or advertising.

ITEM 3. Defaults Upon Senior Securities.

We have commitments to pay investors and lenders $40,553,920 comprising principal and accrued interest on various convertible notes, non-convertible notes and loans payable through November 30, 2017. Due to our lack of financial resources, the Company was unable to make various required principal and interest payments under a number of notes payable, and in 2017, the Company has been successful in restructuring a total of approximately $33.7 million of debt (the “Restructured Debt”) through agreements reached with all of the Company’s secured creditors and the majority of the Company’s unsecured creditors. Pursuant to these restructuring agreements, any and all defaults and penalties with respect to the Restructured Debt have been waived, approximately $9.3 million in accrued interest has been forgiven, and approximately $20.9 million will be converted into approximately 14.1 million shares of the Company’s common stock upon stockholder approval of a 1-for-7 reverse stock split and the election a new board of directors. Prior to the restricting of the Restructured Debt, the Company was in potential default on $13,535,679 of debt. However, as of the date of filing, all notes payable other than $7,289,838 have been restructured and any potential defaults with respect to this restructured amount have been resolved.

As of the date of this filing, Robert Kopple, the Company’s Vice Chairman of the Board, is the only significant unsecured note holder that has not agreed to restructure his debt. Mr. Kopple claims to be owed approximately $5.4 million plus interest and approximately 22 million warrants on terms significantly preferable to other similarly-situated unsecured creditors. To-date, Mr. Kopple has not accepted the Company’s multiple offers to restructure his debt. The Company is presently engaged in a dispute with Mr. Kopple relating to the debt and securities which Mr. Kopple claims to be owed to him and his affiliates by the Company. See, “Note 3 – Notes Payable”, “Note 5 – Related Parties Transactions”, “Note 8 –Subsequent Events” to the Company’s condensed financial statements and “Liquidity and Capital Resources” in “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” elsewhere in this quarterly report on Form 10-Q for additional information regarding amounts that may be owed under the Company’s notes payable and the recent restructuring of certain Company debt.

ITEM 4. Mine Safety Disclosures

Not applicable.

ITEM 5. Other Information.

None.

ITEM 6. Exhibits

31.1	Certifications pursuant to Rule 13a-14 under the Securities Exchange Act of 1934.

31.2	Certifications pursuant to Rule 13a-14 under the Securities Exchange Act of 1934.

32.1	Certification of CEO and CFO Pursuant to 18 U.S.C. § 1350, as Adopted Pursuant to § 906 of the Sarbanes-Oxley Act of 2002.

101.INS	XBRL Instance Document

101.SCH	XBRL Schema Document

101.CAL	XBRL Calculation Linkbase Document

101.DEF	XBRL Definition Linkbase

101.LAB	XBRL Label Linkbase Document

101.PRE	XBRL Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AURA SYSTEMS, INC.
	(Registrant)

	Date: January 19, 2018

	By:	/s/ Melvin Gagerman
		Melvin Gagerman
		Acting Chief Financial Officer
		(Principal Financial and Accounting Officer and
		Duly Authorized Officer)

EX-31.1 2 f10q1117ex31-1_aurasystems.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION

I, Melvin Gagerman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Aura Systems, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 19, 2018	By:	/s/ Melvin Gagerman
		Melvin Gagerman
		Chief Executive Officer

EX-31.2 3 f10q1117ex31-2_aurasystems.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION

I, Melvin Gagerman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Aura Systems, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 19, 2018	By:	/s/ Melvin Gagerman
		Melvin Gagerman
		Acting Chief Financial Officer

EX-32.1 4 f10q1117ex32-1_aurasystems.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the period ended November 30, 2017 of Aura Systems, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Melvin Gagerman, Chief Executive Officer and acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.

	By:	/s/ Melvin Gagerman
		Melvin Gagerman
		Chief Executive Officer,
		Acting Chief Financial Officer

Date: January 19, 2018

EX-101.INS 5 ausi-20171130.xml XBRL INSTANCE FILE 0000826253 ausi:UnsecuredConvertiblePromissoryNoteMember 2012-08-10 0000826253 ausi:UnsecuredConvertiblePromissoryNoteMember 2012-08-01 2012-08-10 0000826253 ausi:UnsecuredConvertiblePromissoryNoteMember 2012-10-02 0000826253 ausi:UnsecuredConvertiblePromissoryNoteMember 2012-10-01 2012-10-02 0000826253 ausi:UnsecuredConvertiblePromissoryNoteMember 2013-02-28 0000826253 ausi:UnsecuredConvertiblePromissoryNoteOneMember 2013-02-28 0000826253 ausi:UnsecuredConvertiblePromissoryNoteTwoMember 2013-02-28 0000826253 ausi:UnsecuredConvertiblePromissoryNoteMember 2013-02-24 2013-02-28 0000826253 ausi:UnsecuredConvertiblePromissoryNoteOneMember 2013-02-24 2013-02-28 0000826253 ausi:UnsecuredConvertiblePromissoryNoteTwoMember 2013-02-24 2013-02-28 0000826253 ausi:KenmontCapitalPartnersMember us-gaap:ConvertibleNotesPayableMember 2013-05-07 0000826253 ausi:LpdInvestmentsMember us-gaap:ConvertibleNotesPayableMember 2013-05-07 0000826253 ausi:HolderMember us-gaap:ConvertibleNotesPayableMember 2013-05-07 0000826253 ausi:UnsecuredConvertiblePromissoryNoteMember 2013-05-01 2013-05-07 0000826253 ausi:KenmontCapitalPartnersMember us-gaap:ConvertibleNotesPayableMember 2013-05-01 2013-05-07 0000826253 ausi:LpdInvestmentsMember us-gaap:ConvertibleNotesPayableMember 2013-05-01 2013-05-07 0000826253 ausi:HolderMember us-gaap:ConvertibleNotesPayableMember 2013-05-01 2013-05-07 0000826253 ausi:HolderMember us-gaap:ConvertibleNotesPayableMember 2013-06-20 0000826253 ausi:HolderMember us-gaap:ConvertibleNotesPayableMember 2013-06-19 2013-06-20 0000826253 ausi:HolderMember us-gaap:BoardOfDirectorsChairmanMember ausi:UnsecuredConvertibleNotesAndWarrantsMember 2013-08-19 0000826253 ausi:HolderMember us-gaap:BoardOfDirectorsChairmanMember ausi:UnsecuredConvertibleNotesAndWarrantsMember 2013-08-18 2013-08-19 0000826253 2016-02-29 0000826253 2016-09-01 2016-11-30 0000826253 2016-03-01 2016-11-30 0000826253 2016-11-30 0000826253 us-gaap:DirectorMember 2017-01-24 0000826253 us-gaap:DirectorMember 2017-01-05 2017-01-24 0000826253 ausi:JointVentureAgreementMember 2017-01-27 0000826253 ausi:ChineseMember 2017-01-27 0000826253 2017-01-02 2017-01-27 0000826253 ausi:ChineseMember 2017-01-02 2017-01-27 0000826253 ausi:HolderMember 2017-01-13 2017-01-30 0000826253 ausi:HolderMember us-gaap:UnsecuredDebtMember 2017-02-21 0000826253 ausi:HolderMember us-gaap:UnsecuredDebtMember 2017-02-18 2017-02-21 0000826253 2017-02-28 0000826253 us-gaap:UnsecuredDebtMember us-gaap:OfficerMember 2017-02-28 0000826253 ausi:AccruedInterestMember us-gaap:OfficerMember 2017-02-28 0000826253 us-gaap:OfficerMember 2017-02-28 0000826253 ausi:TwoThousandSixPalnMember 2017-02-28 0000826253 ausi:TwoThousandSixPalnMember us-gaap:MaximumMember 2017-02-28 0000826253 ausi:TwoThousandSixPalnMember us-gaap:MinimumMember 2017-02-28 0000826253 us-gaap:UnsecuredDebtMember us-gaap:DirectorMember 2017-02-28 0000826253 us-gaap:DirectorMember ausi:AccruedInterestMember 2017-02-28 0000826253 ausi:NotesPayableMember 2017-02-28 0000826253 us-gaap:ConvertibleNotesPayableMember 2017-02-28 0000826253 ausi:ConvertibleOneMember 2017-02-28 0000826253 ausi:ConvertibleTwoMember 2017-02-28 0000826253 ausi:ConvertibleThreeMember 2017-02-28 0000826253 ausi:ConvertibleFourMember 2017-02-28 0000826253 us-gaap:WarrantMember 2017-02-28 0000826253 us-gaap:WarrantMember us-gaap:MaximumMember 2017-02-28 0000826253 us-gaap:WarrantMember us-gaap:MinimumMember 2017-02-28 0000826253 2017-09-01 2017-11-30 0000826253 ausi:UnsecuredConvertiblePromissoryNoteMember 2017-09-01 2017-11-30 0000826253 2017-03-01 2017-11-30 0000826253 ausi:TwoThousandSixPalnMember 2017-03-01 2017-11-30 0000826253 us-gaap:ConvertibleNotesPayableMember 2017-03-01 2017-11-30 0000826253 ausi:ConvertibleOneMember 2017-03-01 2017-11-30 0000826253 ausi:ConvertibleTwoMember 2017-03-01 2017-11-30 0000826253 ausi:ConvertibleThreeMember 2017-03-01 2017-11-30 0000826253 ausi:ConvertibleFourMember 2017-03-01 2017-11-30 0000826253 us-gaap:WarrantMember 2017-03-01 2017-11-30 0000826253 ausi:RangeOfExercisePricesMember 2017-03-01 2017-11-30 0000826253 ausi:RangeOfExercisePricesOneMember 2017-03-01 2017-11-30 0000826253 ausi:RangeOfExercisePricesTwoMember 2017-03-01 2017-11-30 0000826253 ausi:RangeOfExercisePricesThreeMember 2017-03-01 2017-11-30 0000826253 us-gaap:ChiefExecutiveOfficerMember 2017-03-01 2017-11-30 0000826253 ausi:StockOptionsPlansExercisePriceRangeMember 2017-03-01 2017-11-30 0000826253 ausi:RangeOfExercisePricesFourMember 2017-03-01 2017-11-30 0000826253 us-gaap:CommonStockMember us-gaap:CorporateJointVentureMember 2017-03-01 2017-11-30 0000826253 us-gaap:CommonStockMember ausi:SettlementAgreementMember 2017-03-01 2017-11-30 0000826253 us-gaap:CommonStockMember ausi:ConsultingAgreementMember 2017-03-01 2017-11-30 0000826253 2017-11-30 0000826253 ausi:UnsecuredConvertiblePromissoryNoteMember 2017-11-30 0000826253 us-gaap:DirectorMember 2017-11-30 0000826253 us-gaap:UnsecuredDebtMember us-gaap:OfficerMember 2017-11-30 0000826253 ausi:AccruedInterestMember us-gaap:OfficerMember 2017-11-30 0000826253 us-gaap:OfficerMember 2017-11-30 0000826253 ausi:TwoThousandSixPalnMember 2017-11-30 0000826253 ausi:TwoThousandSixPalnMember us-gaap:MaximumMember 2017-11-30 0000826253 ausi:TwoThousandSixPalnMember us-gaap:MinimumMember 2017-11-30 0000826253 us-gaap:UnsecuredDebtMember us-gaap:DirectorMember 2017-11-30 0000826253 us-gaap:DirectorMember ausi:AccruedInterestMember 2017-11-30 0000826253 ausi:NotesPayableMember 2017-11-30 0000826253 us-gaap:ConvertibleNotesPayableMember 2017-11-30 0000826253 ausi:ConvertibleOneMember 2017-11-30 0000826253 ausi:ConvertibleTwoMember 2017-11-30 0000826253 ausi:ConvertibleThreeMember 2017-11-30 0000826253 ausi:ConvertibleFourMember 2017-11-30 0000826253 us-gaap:WarrantMember 2017-11-30 0000826253 us-gaap:WarrantMember us-gaap:MaximumMember 2017-11-30 0000826253 us-gaap:WarrantMember us-gaap:MinimumMember 2017-11-30 0000826253 ausi:RangeOfExercisePricesMember 2017-11-30 0000826253 ausi:RangeOfExercisePricesOneMember 2017-11-30 0000826253 ausi:RangeOfExercisePricesTwoMember 2017-11-30 0000826253 ausi:RangeOfExercisePricesThreeMember 2017-11-30 0000826253 us-gaap:ChiefExecutiveOfficerMember 2017-11-30 0000826253 ausi:StockOptionsPlansExercisePriceRangeMember 2017-11-30 0000826253 ausi:RangeOfExercisePricesFourMember 2017-11-30 0000826253 us-gaap:ChiefExecutiveOfficerMember ausi:AccruedInterestMember 2017-11-30 0000826253 us-gaap:ChiefExecutiveOfficerMember us-gaap:UnsecuredDebtMember 2017-11-30 0000826253 ausi:NotesPayableMember us-gaap:MinimumMember 2017-11-30 0000826253 ausi:NotesPayableMember us-gaap:MaximumMember 2017-11-30 0000826253 us-gaap:OfficerMember us-gaap:ConvertibleNotesPayableMember 2017-11-30 0000826253 us-gaap:BoardOfDirectorsChairmanMember 2017-11-30 0000826253 ausi:RangeOfExercisePricesFourMember us-gaap:MaximumMember 2017-11-30 0000826253 ausi:RangeOfExercisePricesFourMember us-gaap:MinimumMember 2017-11-30 0000826253 ausi:RangeOfExercisePricesOneMember us-gaap:MinimumMember 2017-11-30 0000826253 ausi:RangeOfExercisePricesOneMember us-gaap:MaximumMember 2017-11-30 0000826253 2018-01-16 xbrli:shares iso4217:USD iso4217:USDxbrli:shares utr:sqft xbrli:pure ausi:Notes AURA SYSTEMS INC 0000826253 false AUSI --02-28 10-Q 2017-11-30 2018 Q3 Smaller Reporting Company 126608391

22175

111374

255869

1178153

2894

6588

258763

1184741

3500

250000

262263

1438241

4943559

4827902

5939251

7082010

641751

670751

1000000

4776938

3413058

2920172

3304445

4177283

6629763

14982041

29669693

3587322

2098616

14982041

8890574

30364278

3029930

2040533

14982041

10010053

29141

35268

82000

53068647

57292207

53068647

57292207

11399

12661

410499597

412666277

-463317380

-468532904

-52806384

-55853966

262263

1438241

0.0001

150000000

113991432

126608391

113991432

126608391

321

34209

25250

470725

1319146

822616

1753419

471046

1353355

847866

1778669

-471046

-1353355

-847866

-1778669

602674

2254424

802272

2628323

70288

1767

-11396

-808532

-602674

-2182369

-813668

-3436855

-1073720

-3535724

-1661534

-5215524

-0.01

-0.03

-0.01

-0.04

113951432

113916887

126608391

125324765

310723

137583

402063

342020

175793

235985

63622

667118

192330

43417

177737

990205

-2115

-100101

3694

2559161

1943520

-752305

-2064340

250000

9750000

250000

-250000

1000000

641490

1434593

197970

200014

1000000

841504

3236623

89199

922284

950000 150000 15588

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NOTE 1 – ACCOUNTING POLICIES<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Accounting principles<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the opinion of management, the accompanying balance sheets and related interim statements of income and comprehensive income, and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended February 28, 2017 filed on September 18, 2017 with the U.S. Securities and Exchange Commission.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Estimates<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Recently Issued Accounting Pronouncements<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this Update supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this Update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU No. 2016-02 on our financial statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) that clarifies how to apply revenue recognition guidance related to whether an entity is a principal or an agent. ASU 2016-08 clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to the customer and provides additional guidance about how to apply the control principle when services are provided and when goods or services are combined with other goods or services. The effective date for ASU 2016-08 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. The Company has not yet determined the impact of ASU 2016-08 on its financial statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which provides further guidance on identifying performance obligations and improves the operability and understandability of licensing implementation guidance. The effective date for ASU 2016-10 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years.  In May 2016, the FASB issued ASU 2016-12 “Revenue from Contracts with Customers (Topic 606) - Narrow-Scope Improvements and Practical Expedients,” which amends the guidance on transition, collectability, non-cash consideration, and the presentation of sales and other similar taxes. ASU 2016-12 clarifies that, for a contract to be considered completed at transition, all (or substantially all) of the revenue must have been recognized under legacy GAAP. In addition, ASU 2016-12 clarifies how an entity should evaluate the collectability threshold and when an entity can recognize nonrefundable consideration received as revenue if an arrangement does not meet the standard’s contract criteria. The standard allows for both retrospective and modified retrospective methods of adoption. The Company has not yet determined the impact of ASU 2016-10 on its financial statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Statements,” which requires companies to measure credit losses utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2019 (fiscal year 2021 for the Company). The Company has not yet determined the potential effects of the adoption of ASU 2016-13 on its Financial Statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which aims to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. ASU 2016-15 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017 (fiscal year 2019 for the Company). The Company has not yet determined the potential effects of the adoption of ASU 2016-15 on its Financial Statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Reclassifications<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Certain reclassifications have been made to the comparative financial statements to conform to the current period presentation.</div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NOTE 3 – NOTES PAYABLE<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Notes payable consisted of the following:<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">    <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">November 30, 2017</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">February 28, 2017</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 1160px; font-stretch: normal;">Demand notes payable, at 10% and 16%</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 157px; text-align: right; font-stretch: normal;">3,413,058</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 156px; text-align: right; font-stretch: normal;">3,782,238</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px 0px 0px 0.125in; text-indent: -10pt; font-stretch: normal;">Convertible Promissory Note dated August 10, 2012, due August 10, 2017, convertible into shares of our common stock at a price of $0.76 per share. The note carries an interest rate of 7% with interest only payments due on the 10th of each month with the principal payment due on the maturity date. To-date, the Company has not made any interest payments as set forth in this note.</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">1,000,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">972,632</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px 0px 0px 0.125in; text-indent: -10pt; font-stretch: normal;">Convertible Promissory Note dated October 2, 2012, due October 2, 2017, convertible into shares of our common stock at a price of $0.76 per share. The note carries an interest rate of 7% with interest only payments due on the 2nd of each month with the principal payment due on the maturity date. To-date, the Company has not made any interest payments as set forth in this note.</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">500,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">483,951</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px 0px 0px 0.125in; text-indent: -10pt; font-stretch: normal;">Senior secured convertible notes dated May 7, 2013, due May 7, 2014, convertible into shares of our common stock at a price of $0.75 per share. The note was not repaid.</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">2,395,700</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">2,395,700</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px 0px 0px 0.125in; text-indent: -10pt; font-stretch: normal;">Senior secured convertible notes dated June 20, 2013, due June 20, 2014, convertible into shares of our common stock at a price of $0.50 per share. The note was not repaid.</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">325,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">325,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px 0px 0px 0.125in; text-indent: -10pt; font-stretch: normal;">Convertible notes dated April 2016 thru November 2017. The notes carry an interest rate of 5% and might be converted into shares of Company’s common stock if the shareholders approve a 1:7’ reverse stock split.</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">2,409,063</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">994,700</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times,;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">10,042,821</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">8,954,221</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">Less: Current portion</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">10,042,821</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">8,954,221</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">Long-term portion</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">CONVERTIBLE DEBT<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On May 7, 2013, the Company transferred 4 notes payable with a total principal value of $1,000,000 together with accrued interest, and consulting fees to a senior secured convertible note with a principal value of $1,087,000 and warrants to Kenmont Capital Partners. This new note has a 1-year maturity date and is convertible into shares of common stock at the conversion price of $0.75 per share. The warrants entitle the holder to acquire 1,449,333 shares of common stock, have an initial exercise price of $0.75 per share, and have a 7-year term. The Company recorded $342,020 as a discount, which will be amortized over the life of the note.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On May 7, 2013, the Company transferred 2 note payables with a total principal value of $550,000 together with accrued interest to a senior secured convertible note with a principal value of $558,700 and warrants to LPD Investments, Ltd. This new note has a 1-year maturity date and is convertible into shares of common stock at the conversion price of $0.75 per share. The warrants entitle the holder to acquire 744,933 shares of common stock, have an initial exercise price of $0.75 per share, and have a 7-year term. The Company recorded $175,793 as a discount, which will be amortized over the life of the note.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On May 7, 2013, the Company entered into an agreement with an individual for the sale of a secured convertible note payable in the original principal amount of $750,000 and warrants. This note has a 1-year maturity date and is convertible into shares of common stock at the conversion price of $0.75 per share. The warrants entitle the holder to acquire 1,000,000 shares of common stock, have an initial exercise price of $0.75 per share, and have a 7-year term. The Company recorded $235,985 as a discount, which will be amortized over the life of the note.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On June 20, 2013, the Company entered into an agreement with four individuals for the sale of secured convertible notes payable in the original amount of $325,000 and warrants. These Notes have a 1-year maturity date and are convertible into shares of common stock at the conversion price of $0.50 per share. The warrants entitle the holders to acquire 433,334 shares of common stock, have an initial exercise price of $0.75 per share, and have a 7-year term. The Company recorded $63,622 as a discount, which will be amortized over the life of the notes.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On August 19, 2013, the Company entered into an agreement with a member of its Board of Directors for the sale of $2,500,000 of unsecured convertible notes payable and warrants. These notes carry a base interest rate of 9.5%, have a 4-year maturity date and are convertible into shares of common stock at the conversion price of $0.50 per share. The warrants entitle the holder to acquire 5,000,000 shares of common stock, have an initial exercise price of $0.75 per share and have a 7-year term. The Company recorded $667,118 as a discount, which will be amortized over the life of the note.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">All convertible notes payable are due within twelve months or have not been paid when originally due.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">CONVERTIBLE PROMISSORY NOTES<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At February 28, 2013, the three other unsecured convertible promissory notes payable amounted to $1,447,938, net of discounts of $402,063. These convertible notes bear interest at 7% per annum, and are convertible into common stock of the Company at $0.76 per share (as well as variable conversion rates as described below). These notes are due on August 10, 2017, October 2, 2017, and January 4, 2013. On May 7, 2013, the note due on January 4, 2013 was converted into a portion of the note due June 15, 2013, which carries an interest rate of 12%.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the quarter ended November 30, 2017, the company entered into agreements with various individuals for the aggregate sale of $615,953 of unsecured convertible notes and warrants. Pursuant to the terms of these notes, such notes will be converted in their entirety into shares of common stock of the Company at the conversion price of $0.07 per share upon stockholder approval of a 1-for-7 reverse stock split. The warrants entitle the holders to acquire up to an aggregate of 132,000 shares of common stock and have an initial exercise price of $0.20 per share which will be adjusted to $1.40 per share upon stockholder approval of a 1-for-7 reverse stock split. The stockholders approved the reverse stock split at the Company’s stockholder meeting on January 11, 2018.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">7% Convertible Promissory Notes:<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On August 10, 2012 the Company entered into an agreement with an individual for the sale of an unsecured convertible promissory note in the original principal amount of $1,000,000. This convertible promissory note is due and payable on August 10, 2017 and bears an interest rate is 7% per annum.  Interest on the unpaid principal amount of this note is payable monthly in arrears, on the tenth day of each calendar month, commencing September 10, 2012. Interest is computed on the actual number of days elapsed over a 360-day year. The Holder has the right to convert any outstanding and unpaid principal portion of this convertible promissory note into shares of common stock. The company recorded $310,723 as a debt discount, which will be amortized over the life of the note.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 2, 2012 the Company entered into an agreement with an individual for the sale of an unsecured convertible promissory note in the original principal amount of $500,000. This convertible promissory note is due and payable on October 2, 2017 and bears an interest rate is 7% per annum.  Interest on the unpaid principal amount of this note is payable monthly in arrears on the second day of each calendar month, commencing November 2, 2012. Interest is computed on the actual number of days elapsed over a 360-day year. The Holder has the right to convert any outstanding and unpaid principal portion of this convertible promissory note into shares of common stock. The company recorded $137,583 as a debt discount, which will be amortized over the life of the note.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On January 30, 2017 the Company entered into an agreement entitled First Amendment to Transaction Documents with five of seven of its secured creditors. These creditors hold a security interest in all of the Company’s assets except for its patents and other intellectual properties. The original agreement dated May 7, 2013 provided that if the holders of at least 75% of the stock issuable upon conversion of the convertible notes votes to amend the agreement, then such amendments will be binding on all the secured creditors. The five secured creditors signing the amendment total in excess of 95% of the issuable stock upon conversion and, therefore the agreement is binding on all seven of the secured creditors. The amended agreement provides that all accrued and unpaid interest will be added to the principal amount, the amended notes bear interest at the rate of 0% through the sooner of (i) January 15, 2018 or (ii) the fifth business day following a stockholder meeting and 5% per annum thereafter, subject to reduction to comply with applicable law, and mature in 60 months from the effective date of a proposed 1-for-7 reverse stock split (which may only be effected if approved by the stockholders at the next annual meeting of stockholders). Upon certain financings, within five business days following stockholder approval of a 1-for-7 reverse stock split, the Company is obligated to make a payment to the holders of the amended notes in the amount of 20% of the outstanding secured notes. Upon the effectiveness of a proposed 1-for-7 reverse stock split, the remaining 80% balance of the amended notes is converted into shares of the Company’s common stock. After the effectiveness of a proposed 1-for-7 reverse stock split, the secured note holders may voluntarily convert the unpaid principal and interest thereon into the Company’s common stock at the conversion price of $1.40 per share.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On February 21, 2017 the Company entered into debt refinancing agreements with several debt holders relating to aggregate unsecured debt totaling $2,237,456 including interest of $489,466. This refinancing agreement waives any past events of default and provides for new five-year convertible notes which bear no interest through the sooner of (i) January 15, 2018 or (ii) the fifth business day following a stockholder meeting and 5% per annum thereafter. Upon stockholder approval of a 1-for-7 reverse stock split, these notes will be converted into a total of 1,164,555 shares of common stock. The notes also provide various default provisions.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The stockholders approved the reverse split at the Company’s stockholder meeting on January 11, 2018.</div>

<div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NOTE 5 – SHAREHOLDERS’ EQUITY <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Common Stock <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the nine months ended November 30, 2017, we issued 5,000,000 shares of common stock for $1,000,000 in conjunction with our Chinese Joint Venture, we issued 5,116,959 shares of common stock valued at $665,204 as part of a settlement agreement, and we issued 2,500,000 shares of common stock valued at $325,000 in connection with a consulting agreement. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the nine months ended November 30, 2016, we issued 950,000 shares of common stock as a settlement for a note payable balance of $150,000 plus accrued interest of $15,288. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Employee Stock Options <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the nine months ended November 30, 2017, there were no stock options granted to employees. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In September, 2006, our Board of Directors adopted the 2006 Employee Stock Option Plan. Activity in this plan is as follows: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">2006 Plan</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted- Average Exercise Price</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Aggregate Intrinsic Value</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Options</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 1003px;">Outstanding, February 28, 2017</td> <td style="width: 16px;"> </td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 142px; text-align: right;">$0.75-$1.00</td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 16px;"> </td> <td style="width: 16px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">0.00</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 141px; text-align: right;">7,224,000</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Cancelled</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding-bottom: 1.5pt;">Granted</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 1.5pt;">Outstanding, November 30, 2017</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$0.75-$1.00</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0.00</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">7,224,000</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The exercise prices for the options outstanding at November 30, 2017, and information relating to these options is as follows: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="13">Options Outstanding</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="9">Exercisable Options</td> </tr> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">Range of  Exercise Price</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Number</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted Average Remaining  Life</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted Average Exercise Price</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">Weighted Average Remaining Life</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Number</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted Average Exercise Price</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> </tr> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> $0.75-$1.00</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">7,224,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">2.25 years</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.79</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">2.25 years</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">7,224,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.79</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Warrants <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Activity in issued and outstanding warrants is as follows: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Shares</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Exercise Prices</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 1191px;">Outstanding, February 28, 2017</td> <td style="width: 16px;"> </td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 142px; text-align: right;">26,454,021</td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 141px; text-align: right;">$0.10-$1.00</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,400,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">.20</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 1.5pt;">Cancelled</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">406,941</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1.00</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="padding-bottom: 4pt;">Outstanding, November 30, 2017</td> <td style="padding-bottom: 4pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">27,447,080</td> <td style="text-align: left; padding-bottom: 4pt;"> </td> <td style="padding-bottom: 4pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$0.10-$1.00</td> <td style="text-align: left; padding-bottom: 4pt;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The exercise prices for the warrants outstanding at November 30, 2017, and information relating to these warrants is as follows: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">Range of Exercise Prices</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Stock Warrants Outstanding</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Stock Warrants Exercisable</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted- Average Remaining Contractual Life</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted- Average  Exercise Price of Warrants Outstanding</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted- Average Exercise Price of Warrants Exercisable</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Intrinsic Value</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> </tr> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 220px; text-align: center; font-stretch: normal;">$0.20</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 189px; text-align: right; font-stretch: normal;">1,400,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 189px; text-align: right; font-stretch: normal;">1,400,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 173px; text-align: center; font-stretch: normal;">51 months</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 172px; text-align: right; font-stretch: normal;">0.20</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 172px; text-align: right; font-stretch: normal;">0.20</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 172px; text-align: right; font-stretch: normal;">0.00</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td> </tr> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">$0.10-$0.75</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">18,381,012</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">18,381,012</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">41 months</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.55</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.41</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.00</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> </tr> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">$0.75</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">1,082,734</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">1,082,734</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">39 months</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.00</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> </tr> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">$0.75</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">1,000,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">1,000,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">29 months</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.00</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> </tr> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">$0.75-$1.00</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">5,583,334</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">5,583,334</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">26 months</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.00</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> </tr> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> </tr> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;">27,447,080</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;">27,447,080</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td> </tr> </table> </div>

<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="13">Options Outstanding</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="9">Exercisable Options</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">Range of  Exercise Price</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Number</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted Average Remaining  Life</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted Average Exercise Price</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">Weighted Average Remaining Life</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Number</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted Average Exercise Price</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> $0.75-$1.00</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">7,224,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">2.25 years</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.79</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">2.25 years</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">7,224,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.79</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr></table>

<div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">Range of Exercise Prices</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Stock Warrants Outstanding</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Stock Warrants Exercisable</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted- Average Remaining Contractual Life</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted- Average  Exercise Price of Warrants Outstanding</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Weighted- Average Exercise Price of Warrants Exercisable</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Intrinsic Value</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 220px; text-align: center; font-stretch: normal;">$0.20</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 189px; text-align: right; font-stretch: normal;">1,400,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 189px; text-align: right; font-stretch: normal;">1,400,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 173px; text-align: center; font-stretch: normal;">51 months</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 172px; text-align: right; font-stretch: normal;">0.20</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 172px; text-align: right; font-stretch: normal;">0.20</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 172px; text-align: right; font-stretch: normal;">0.00</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 15px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">$0.10-$0.75</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">18,381,012</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">18,381,012</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">41 months</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.55</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.41</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.00</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">$0.75</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">1,082,734</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">1,082,734</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">39 months</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.00</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">$0.75</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">1,000,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">1,000,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">29 months</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.00</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">$0.75-$1.00</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">5,583,334</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">5,583,334</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;">26 months</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.75</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;">0.00</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;">27,447,080</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;">27,447,080</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"> </td></tr></table></div>

752305

2064340

45000

3782238

972632

483951

2395700

325000

994700

3413058

1000000

500000

2395700

325000

2409063

8954221

10042821

8954221

10042821

0.07

0.095

0.05

0.10

0.07

0.05

0.10

0.16

2017-08-10

2017-10-02

2017-08-10

2017-10-02

2013-01-04

2017-08-10

2017-10-02

2014-05-07

2014-06-20

2017-11-30

0.76

0.75

0.50

0.76

0.75

0.50

1:7` reverse stock split.

1000000

500000

1000000

550000

2500000

1447938

1087000

558700

750000

325000

23872614

615953

P7Y P7Y P7Y P7Y P7Y

0.75

1.00

0.10

1.00

0.10

1449333

744933

1000000

433334

5000000

4 2

P1Y

P4Y

P5Y

Interest on the unpaid principal amount of this note is payable monthly in arrears, on the tenth day of each calendar month, commencing September 10, 2012. Interest is computed on the actual number of days elapsed over a 360-day year.

Interest on the unpaid principal amount of this note is payable monthly in arrears on the second day of each calendar month, commencing November 2, 2012. Interest is computed on the actual number of days elapsed over a 360-day year.

The note due on January 4, 2013 was converted into a portion of the note due June 15, 2013, which carries an interest rate of 12%.

The holders of at least 75% of the stock issuable upon conversion of the convertible notes votes to amend the agreement, then such amendments will be binding on all the secured creditors. The five secured creditors signing the amendment total in excess of 95% of the issuable stock upon conversion and, therefore the agreement is binding on all seven of the secured creditors. The amended agreement provides that all accrued and unpaid interest will be added to the principal amount, the amended notes bear interest at the rate of 0% through the sooner of (i) January 15, 2018 or (ii) the fifth business day following a stockholder meeting and 5% per annum thereafter, subject to reduction to comply with applicable law, and mature in 60 months from the effective date of a proposed 1-for-7 reverse stock split (which may only be effected if approved by the stockholders at the next annual meeting of stockholders). Upon certain financings, within five business days following stockholder approval of a 1-for-7 reverse stock split, the Company is obligated to make a payment to the holders of the amended notes in the amount of 20% of the outstanding secured notes. Upon the effectiveness of a proposed 1-for-7 reverse stock split, the remaining 80% balance of the amended notes is converted into shares of the Company's common stock. After the effectiveness of a proposed 1-for-7 reverse stock split, the secured note holders may voluntarily convert the unpaid principal and interest thereon into the Company's common stock at the conversion price of $1.40 per share.

Upon stockholder approval of a 1-for-7 reverse stock split

Pursuant to the terms of these notes, such notes will be converted in their entirety into shares of common stock of the Company at the conversion price of $0.07 per share upon stockholder approval of a 1-for-7 reverse stock split. The warrants entitle the holders to acquire up to an aggregate of 132,000 shares of common stock and have an initial exercise price of $0.20 per share which will be adjusted to $1.40 per share upon stockholder approval of a 1-for-7 reverse stock split. The stockholders approved the reverse stock split at the Company's stockholder meeting on January 11, 2018.

2237456

489466

1164555

3099842

2781312

202036

2562375

4073662

75000

25000

1.00

0.75

1.00

0.75

0.00

7224000

0.75

1.00

7224000

P2Y2M30D

0.79

P2Y2M30D

7224000

0.79

26454021

7224000

1400000

1082734

1000000

22000000

1400000

406941

0.20 1.00

0.20

0.75

1.00

0.75

0.10

0.75

27447080 1400000 18381012 1082734 1000000 5583334

P51M

P41M

P39M

P29M

P26M

0.20 0.55 0.75 0.75 0.75 0.20 0.41 0.75 0.75 0.75

0.00

1000000

665204

325000

950000

5000000

5116959

2500000

150000

15288

2014-04-05

993647

1119480

8890574

1145258

2000000

11982041

7403705

Stockholder approval of a 1-for-7 reverse stock split within eighteen months of entering into that agreement; the remaining balance may thereafter be converted at any time. In the absence of stockholder approval of a 1-for-7 reverse stock split within eighteen months, the refinancing agreement will become null and void. The Company has elected to continue to accrue interest on this agreement until such time as the 1-for-7 reverse stock split has been approved. The stockholders approved the reverse split at the Company's stockholder meeting on January 11, 2018.

20000

10000

0.49

2000000

0.20

0.51

10000000

1250000

5400000

Weighted average number of shares used to compute basic and diluted loss per share is the same since the effect of the dilutive securities is anti-dilutive.

EX-101.SCH 6 ausi-20171130.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Balance Sheets (Parenthetical) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Statements of Cash Flows (Parenthetical) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Related Parties Transactions link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Commitments link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Notes Payable (Parenthetical) (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Notes Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Shareholders' Equity (Details 1) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Shareholders' Equity (Details 2) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Shareholders' Equity (Details 3) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Shareholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Related Parties Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Commitments (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 ausi-20171130_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 ausi-20171130_def.xml XBRL DEFINITION FILE EX-101.LAB 9 ausi-20171130_lab.xml XBRL LABEL FILE Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Trading Symbol Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Filer Category Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Other assets Other current assets Assets, Current Total current assets Deposits Due from Joint Ventures Investment in Joint Venture Assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable Accounts payable Accrued Liabilities, Current Accrued expenses Total Customer advances Investor Advances Current Investor advance The current portion of prepayments received from investor in advance. Notes Payable, Current Notes payable Other Notes Payable, Current Convertible note payable and accrued interest-related party, net of discount Demand notes payable, at 10% and 16% Convertible Notes Payable, Current Convertible notes payable, net of discount Notes payable and accrued interest- related party Unsecured notes payable and accrued interest- related party Notes payable and accrued interest- related party Liabilities, Current Total current liabilities Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders' deficit: Stockholders' deficit: CommonStockValue Common stock, $0.0001 par value; 150,000,000 shares authorized at November 30 and February 28, 2017; 126,608,391 and 113,991,432 issued and outstanding at November 30 and February 28, 2017, respectively Additional paid-in capital Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' deficit Beginning balance Ending balance Liabilities and Equity Total liabilities and stockholders' deficit CommonStockParOrStatedValuePerShare Common stock, par value CommonStockSharesAuthorized Common stock, shares authorized CommonStockSharesIssued Common stock, shares issued Common stock, shares outstanding (in shares) Common stock, shares outstanding Income Statement [Abstract] Revenue, Net Net Revenues Cost of Goods Sold Cost of goods sold Gross Profit Gross Profit Operating Expenses [Abstract] Expenses Research and Development Expense Engineering, research and development expenses Engineering, research and development expenses Selling, General and Administrative Expense Selling, general and administrative expenses Selling, general and administrative expenses Operating Costs and Expenses Total costs and expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other (income) and expense Interest Expense Interest expense, net Interest expense, net Gain (Loss) on Extinguishment of Debt Gain on debt settlement Gain on debt settlement Other Nonoperating Income (Expense) Other (income) expense, net Other (income) expense, net Nonoperating Income (Expense) Total other (income) expense Total other (income) expense Net Income (Loss) Attributable to Parent Net Loss Net Loss Net Loss Net Loss Net Loss Earnings Per Share, Basic and Diluted Total basic and diluted loss per share Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average shares used to compute basic and diluted income (loss) per share Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flow from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile Net loss to net cash used in operating activities Amortization of debt discount Amortization of debt discount Adjustment of Warrants Granted for Services FMV of warrants issued for services Issuance of Stock and Warrants for Services or Claims Stock issued for services Increase (Decrease) in Operating Assets [Abstract] (Increase) decrease in: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Other Current Assets Other current assets and deposit Increase (Decrease) in Operating Liabilities [Abstract] Increase (decrease) in: Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable, customer deposit and accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operations Net Cash Provided by (Used in) Investing Activities [Abstract] Investing Activities: Payments to Acquire Interest in Joint Venture Payments for joint venture agreement Investment in Joint Venture Investment in Joint Venture Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Proceeds from Issuance of Common Stock Issuance of common stock Proceeds from Notes Payable Proceeds from notes payable-net Proceeds from Convertible Debt Proceeds from convertible notes payable Repayments of Notes Payable Payment to notes payable Proceeds from Related Party Debt Proceeds from notes payable-related party, net Proceedsfrominvestoradvance Investor Advance Amount of cash inflow from investor advance Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities: Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash & cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information Cash Paid [Abstract] Cash paid during the period for: Interest Paid, Net Interest Income Taxes Paid Income taxes Non Cash Shares Of Common Stock Issued Common shares issued to settled, shares Non cash shares of common stock issued. Non Cash Note Payable Settled Note payable balance The amount of non cash note payable settled. Non Cash Accrued Interest Accrued interest Non cash accrued interest. Accounting Policies [Abstract] Summary of Significant Accounting Policies [Abstract] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] ACCOUNTING POLICIES Going Concern [Abstract] GOING CONCERN [Text Block] GOING CONCERN The entire disclosure if there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Notes Payable [Abstract] Debt Disclosure [Text Block] NOTES PAYABLE Accrued Expenses [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCRUED EXPENSES Shareholders' Equity [Abstract] Stockholders' Equity Note Disclosure [Text Block] SHAREHOLDERS' EQUITY Related Parties Transactions [Abstract] Related Party Transactions Disclosure [Text Block] RELATED PARTIES TRANSACTIONS Commitments [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS Subsequent Events [Abstract] Subsequent Events [Text Block] SUBSEQUENT EVENTS Basis of Accounting, Policy [Policy Text Block] Accounting principles Use of Estimates, Policy [Policy Text Block] Estimates New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Reclassification, Policy [Policy Text Block] Reclassifications Schedule of Debt [Table Text Block] Schedule of notes payable Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Stock option activity Schedule of 2006 employee stock option plan Exercise price of options outstanding and options information Schedule of exercise price options outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of activity in issued and outstanding warrants Schedule of Share Based Compensation Shares Authorized Under Warrants by Exercise Price Range [Table Text Block] Schedule of exercise prices warrants outstanding Exercise prices for the warrants outstanding and warrant information Tabular disclosure of warrant exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under warrant, weighted average exercise price and remaining contractual terms. Going Concern Textual [Abstract] Going Concern (Textual) Net cash used in operating activities Cash flows from operating activities Net cash used in operations Area of Land Area of land Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Notes Payable [Member] Notes Payable [Member] Demand notes payable [Member] Notes payable. Convertible Notes Payable [Member] Convertible Secured Notes [Member] Convertible Promissory Note dated August 10, 2012 [Member] Convertible One [Member] Convertible One [Member] Convertible Promissory Note dated October 2, 2012 [Member] Convertible one. Convertible Two [Member] Senior secured convertible notes dated May 7, 2013 [Member] Convertible Two [Member] Convertible two. Convertible Three [Member] Senior secured convertible notes dated June 20, 2013 [Member] Convertible Three [Member] Convertible three. Convertible Four [Member] Convertible notes dated April thru February 2017 [Member] Convertible Four [Member] Convertible four. Convertible notes dated April thru November 2017 [Member] Debt Instrument [Line Items] Notes Payable Demand notes payable Notes payable current and long-term portion Convertible Notes Payable Convertible notes payable Convertible note Long-term Debt, Current Maturities Less: Current portion Less: Current portion Convertible note payable, net of discount Long-term portion Long-term portion Range [Axis] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Debt Instrument, Interest Rate, Stated Percentage Notes payable interest rate Interest rate Due date Due date of notes Debt Instrument, Convertible, Conversion Price Conversion price per share of notes payable Stockholders' Equity Note, Stock Split Reverse stock split Kenmont Capital Partners [Member] Kenmont Capital Partners [Member] Kenmont Capital Partners. Lpd Investments [Member] LPD Investments, Ltd [Member] Lpd Investments [Member] LPD Investments. Holder [Member] Holder [Member] Holder. Unsecured Convertible Promissory Note [Member] Unsecured Convertible Promissory Note [Member] Unsecured convertible promissory note. Unsecured Convertible Promissory Note One [Member] Unsecured Convertible Promissory Note One [Member] Unsecured Convertible Promissory Note Two [Member] Unsecured Convertible Promissory Note Two [Member] Title of Individual [Axis] Relationship to Entity [Domain] Board of Directors Chairman [Member] Robert Kopple [Member] Board of Directors [Member] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Unsecured Convertible Notes And Warrants [Member] Unsecured Convertible Notes and Warrants [Member] Unsecured Debt [Member] Unsecured Debt [Member] Notes Payable Textual [Abstract] Notes Payable (Textual) Debt Conversion, Original Debt, Amount Pre conversion debt principal amount Principal value of convertible notes Principal value of convertible notes Debt principal amount Term of warrant Term of warrant Period when holder have a right to buy the shares by exercising the warrant. Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price per common share under warrant one (in dollars per share) Exercise Prices, Outstanding Exercise Prices, Outstanding Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of common shares entitlement on exercise of warrant one (in shares) Number of common shares entitlement on exercise of warrant one (in shares) Number Of Notes Payable To Transferred Number of notes payable to transferred Represents the number of notes payable to transfer. Debt Instrument, Term Notes maturity date, term New debt agreement, term Debt Instrument, Description Description of convertible promissory note Unsecured Debt Aggregate unsecured debt Interest Expense, Long-term Debt Interest of debt Debt Conversion, Converted Instrument, Shares Issued Converted shares of common stock Accrued payroll and related expenses Accrued payroll and related expenses Accrued rent Accrued rent Accrued interest Accrued interest Other Other Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Two Thousand Six Paln [Member] 2006 Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted - Average Exercise Price Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted - Average Exercise Price, Outstanding Weighted - Average Exercise Price, Outstanding Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted - Average Exercise Price, Cancelled Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted - Average Exercise Price, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Aggregate Intrinsic Value, Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Intrinsic Value Aggregate Intrinsic Value, Cancelled Share based compensation arrangement by share based payment award options cancelled intrinsic value. Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value Aggregate Intrinsic Value, Granted Share based compensation arrangement by share based payment award options granted intrinsic value. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Options, Outstanding Number of Options, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of Options, Cancelled Number of Options, Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of Options, Granted EX-101.PRE 10 ausi-20171130_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Nov. 30, 2017	Jan. 16, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	AURA SYSTEMS INC
Entity Central Index Key	0000826253
Amendment Flag	false
Trading Symbol	AUSI
Current Fiscal Year End Date	--02-28
Document Type	10-Q
Document Period End Date	Nov. 30, 2017
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		126,608,391

XML 12 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets (Unaudited) - USD ($)	Nov. 30, 2017	Feb. 28, 2017
Current assets:
Cash and cash equivalents	$ 1,178,153	$ 255,869
Other current assets	6,588	2,894
Total current assets	1,184,741	258,763
Deposits	3,500	3,500
Investment in Joint Venture	250,000
Total assets	1,438,241	262,263
Current liabilities:
Accounts payable	4,827,902	4,943,559
Accrued expenses	7,082,010	5,939,251
Customer advances	670,751	641,751
Investor advance	1,000,000
Notes payable	3,413,058	4,776,938
Convertible note payable and accrued interest-related party, net of discount	3,304,445	2,920,172
Convertible notes payable, net of discount	6,629,763	4,177,283
Notes payable and accrued interest- related party	30,364,278	29,669,693
Total current liabilities	57,292,207	53,068,647
Total liabilities	57,292,207	53,068,647
Commitments and contingencies
Stockholders' deficit:
Common stock, $0.0001 par value; 150,000,000 shares authorized at November 30 and February 28, 2017; 126,608,391 and 113,991,432 issued and outstanding at November 30 and February 28, 2017, respectively	12,661	11,399
Additional paid-in capital	412,666,277	410,499,597
Accumulated deficit	(468,532,904)	(463,317,380)
Total stockholders' deficit	(55,853,966)	(52,806,384)
Total liabilities and stockholders' deficit	$ 1,438,241	$ 262,263

XML 13 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Nov. 30, 2017	Feb. 28, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	126,608,391	113,991,432
Common stock, shares outstanding	126,608,391	113,991,432

XML 14 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (Unaudited) - USD ($)

3 Months Ended

9 Months Ended

Nov. 30, 2017

Nov. 30, 2016

Nov. 30, 2017

Nov. 30, 2016

Income Statement [Abstract]

Net Revenues

Cost of goods sold

Gross Profit

Expenses

Engineering, research and development expenses

25,250

321

25,250

34,209

Selling, general and administrative expenses

822,616

470,725

1,753,419

1,319,146

Total costs and expenses

847,866

471,046

1,778,669

1,353,355

Loss from operations

(847,866)

(471,046)

(1,778,669)

(1,353,355)

Other (income) and expense

Interest expense, net

802,272

602,674

2,628,323

2,254,424

Gain on debt settlement

(70,288)

Other (income) expense, net

11,396

808,532

(1,767)

Total other (income) expense

813,668

602,674

3,436,855

2,182,369

Net Loss

$ (1,661,534)

$ (1,073,720)

$ (5,215,524)

$ (3,535,724)

Total basic and diluted loss per share

$ (0.01)

$ (0.04)

$ (0.03)

Weighted average shares used to compute basic and diluted income (loss) per share

^[1]

126,608,391

113,951,432

125,324,765

113,916,887

[1]	Weighted average number of shares used to compute basic and diluted loss per share is the same since the effect of the dilutive securities is anti-dilutive.

XML 15 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Nov. 30, 2017	Nov. 30, 2016
Cash flow from operating activities:
Net Loss	$ (5,215,524)	$ (3,535,724)
Adjustments to reconcile Net loss to net cash used in operating activities
Amortization of debt discount	43,417	192,330
Gain on debt settlement		(70,288)
FMV of warrants issued for services	177,737
Stock issued for services	990,205
(Increase) decrease in:
Accounts receivable		2,115
Other current assets and deposit	(3,694)	100,101
Increase (decrease) in:
Accounts payable, customer deposit and accrued expenses	1,943,520	2,559,161
Net cash used in operations	(2,064,340)	(752,305)
Investing Activities:
Investment in Joint Venture	(250,000)
Net cash used in investing activities	(250,000)
Financing activities:
Issuance of common stock	1,000,000
Proceeds from notes payable-net		641,490
Proceeds from convertible notes payable	1,434,593
Payment to notes payable	(197,970)
Proceeds from notes payable-related party, net		200,014
Investor Advance	1,000,000
Net cash provided by financing activities:	3,236,623	841,504
Net increase in cash & cash equivalents	922,284	89,199
Cash and cash equivalents at beginning of period	255,869	22,175
Cash and cash equivalents at end of period	1,178,153	111,374
Cash paid during the period for:
Interest
Income taxes

XML 16 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Parenthetical) (Unaudited)	9 Months Ended
Statements of Cash Flows (Parenthetical) (Unaudited)	Nov. 30, 2016 USD ($) shares
Statement of Cash Flows [Abstract]
Common shares issued to settled, shares \| shares	950,000
Note payable balance	$ 150,000
Accrued interest	$ 15,588

XML 17 R7.htm IDEA: XBRL DOCUMENT

Accounting Policies	9 Months Ended
Accounting Policies	Nov. 30, 2017
Accounting Policies [Abstract]
ACCOUNTING POLICIES	NOTE 1 – ACCOUNTING POLICIES Accounting principles In the opinion of management, the accompanying balance sheets and related interim statements of income and comprehensive income, and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended February 28, 2017 filed on September 18, 2017 with the U.S. Securities and Exchange Commission. Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Recently Issued Accounting Pronouncements In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this Update supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this Update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU No. 2016-02 on our financial statements. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) that clarifies how to apply revenue recognition guidance related to whether an entity is a principal or an agent. ASU 2016-08 clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to the customer and provides additional guidance about how to apply the control principle when services are provided and when goods or services are combined with other goods or services. The effective date for ASU 2016-08 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. The Company has not yet determined the impact of ASU 2016-08 on its financial statements. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which provides further guidance on identifying performance obligations and improves the operability and understandability of licensing implementation guidance. The effective date for ASU 2016-10 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. In May 2016, the FASB issued ASU 2016-12 “Revenue from Contracts with Customers (Topic 606) - Narrow-Scope Improvements and Practical Expedients,” which amends the guidance on transition, collectability, non-cash consideration, and the presentation of sales and other similar taxes. ASU 2016-12 clarifies that, for a contract to be considered completed at transition, all (or substantially all) of the revenue must have been recognized under legacy GAAP. In addition, ASU 2016-12 clarifies how an entity should evaluate the collectability threshold and when an entity can recognize nonrefundable consideration received as revenue if an arrangement does not meet the standard’s contract criteria. The standard allows for both retrospective and modified retrospective methods of adoption. The Company has not yet determined the impact of ASU 2016-10 on its financial statements. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Statements,” which requires companies to measure credit losses utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2019 (fiscal year 2021 for the Company). The Company has not yet determined the potential effects of the adoption of ASU 2016-13 on its Financial Statements. In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which aims to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. ASU 2016-15 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017 (fiscal year 2019 for the Company). The Company has not yet determined the potential effects of the adoption of ASU 2016-15 on its Financial Statements. Reclassifications Certain reclassifications have been made to the comparative financial statements to conform to the current period presentation.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Going Concern	9 Months Ended
Going Concern	Nov. 30, 2017
Going Concern [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. During the nine months ended November 30, 2017 and November 30, 2016, the Company incurred losses of $5,215,524 and $3,535,724, respectively and had negative cash flows from operating activities of $2,064,340 and $752,305, respectively. If the Company is unable to generate profits and is unable to continue to obtain financing for its working capital requirements, it may have to curtail its business sharply or cease business altogether. Substantial additional capital resources will be required to fund continuing expenditures related to our research, development, manufacturing and business development activities. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis, to retain its current financing, to obtain additional financing, and ultimately to attain profitability. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that could result from the outcome of this uncertainty. During the next twelve months we intend to restart operations of our AuraGen/VIPER business both domestically and internationally. At the next shareholders meeting the shareholders will vote for an entire new slate of five board candidates. The new board when elected will hire a new management team. In addition we plan to acquire a new facility of approximately 45,000 square feet for operations, as well as, rebuild the engineering QA and sales teams to support the operation. We anticipate being able to fund these additions in the upcoming fiscal year.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Notes Payable

9 Months Ended

Nov. 30, 2017

Notes Payable [Abstract]

NOTES PAYABLE

NOTE 3 – NOTES PAYABLE

Notes payable consisted of the following:

	November 30, 2017		February 28, 2017

Demand notes payable, at 10% and 16%	$	3,413,058	$	3,782,238
Convertible Promissory Note dated August 10, 2012, due August 10, 2017, convertible into shares of our common stock at a price of $0.76 per share. The note carries an interest rate of 7% with interest only payments due on the 10^th of each month with the principal payment due on the maturity date. To-date, the Company has not made any interest payments as set forth in this note.		1,000,000		972,632
Convertible Promissory Note dated October 2, 2012, due October 2, 2017, convertible into shares of our common stock at a price of $0.76 per share. The note carries an interest rate of 7% with interest only payments due on the 2^nd of each month with the principal payment due on the maturity date. To-date, the Company has not made any interest payments as set forth in this note.		500,000		483,951
Senior secured convertible notes dated May 7, 2013, due May 7, 2014, convertible into shares of our common stock at a price of $0.75 per share. The note was not repaid.		2,395,700		2,395,700
Senior secured convertible notes dated June 20, 2013, due June 20, 2014, convertible into shares of our common stock at a price of $0.50 per share. The note was not repaid.		325,000		325,000
Convertible notes dated April 2016 thru November 2017. The notes carry an interest rate of 5% and might be converted into shares of Company’s common stock if the shareholders approve a 1:7’ reverse stock split.		2,409,063		994,700

		10,042,821		8,954,221

Less: Current portion	$	10,042,821	$	8,954,221

Long-term portion	$	-	$	-

CONVERTIBLE DEBT

All convertible notes payable are due within twelve months or have not been paid when originally due.

CONVERTIBLE PROMISSORY NOTES

7% Convertible Promissory Notes:

The stockholders approved the reverse split at the Company’s stockholder meeting on January 11, 2018.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

9 Months Ended

Nov. 30, 2017

Accrued Expenses [Abstract]

ACCRUED EXPENSES

NOTE 4 – ACCRUED EXPENSES

Accrued expenses consisted of the following:

	November 30, 2017		February 28, 2017

Accrued payroll and related expenses	$	2,781,312	$	3,099,842
Accrued rent		202,036		202,036
Accrued interest		4,073,662		2,562,375
Other		25,000		75,000
Total	$	7,082,010	$	5,939,252

Accrued payroll and related expenses consists of salaries and vacation time accrued but not paid to employees due to our lack of financial resources.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

9 Months Ended

Nov. 30, 2017

Shareholders' Equity [Abstract]

SHAREHOLDERS' EQUITY

NOTE 5 – SHAREHOLDERS’ EQUITY

Common Stock

During the nine months ended November 30, 2016, we issued 950,000 shares of common stock as a settlement for a note payable balance of $150,000 plus accrued interest of $15,288.

Employee Stock Options

During the nine months ended November 30, 2017, there were no stock options granted to employees.

In September, 2006, our Board of Directors adopted the 2006 Employee Stock Option Plan. Activity in this plan is as follows:

	2006 Plan
	Weighted- Average Exercise Price		Aggregate Intrinsic Value		Number of Options
Outstanding, February 28, 2017		$0.75-$1.00	$	0.00		7,224,000
Cancelled		-		-		-
Granted		-		-		-
Outstanding, November 30, 2017		$0.75-$1.00	$	0.00		7,224,000

The exercise prices for the options outstanding at November 30, 2017, and information relating to these options is as follows:

Options Outstanding

Exercisable Options

Range of
Exercise
Price

Number

Weighted
Average
Remaining
Life

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life

Number

Weighted
Average
Exercise
Price

$0.75-$1.00

7,224,000

2.25 years

0.79

2.25 years

7,224,000

0.79

Warrants

Activity in issued and outstanding warrants is as follows:

	Number of Shares		Exercise Prices
Outstanding, February 28, 2017		26,454,021		$0.10-$1.00
Granted		1,400,000	$	.20
Exercised		-		-
Cancelled		406,941		1.00
Outstanding, November 30, 2017		27,447,080		$0.10-$1.00

The exercise prices for the warrants outstanding at November 30, 2017, and information relating to these warrants is as follows:

Range of Exercise Prices	Stock Warrants Outstanding		Stock Warrants Exercisable		Weighted- Average Remaining Contractual Life		Weighted- Average Exercise Price of Warrants Outstanding		Weighted- Average Exercise Price of Warrants Exercisable		Intrinsic Value
$0.20		1,400,000		1,400,000		51 months	$	0.20	$	0.20	$	0.00
$0.10-$0.75		18,381,012		18,381,012		41 months	$	0.55	$	0.41	$	0.00
$0.75		1,082,734		1,082,734		39 months	$	0.75	$	0.75	$	0.00
$0.75		1,000,000		1,000,000		29 months	$	0.75	$	0.75	$	0.00
$0.75-$1.00		5,583,334		5,583,334		26 months	$	0.75	$	0.75	$	0.00

		27,447,080		27,447,080

XML 22 R12.htm IDEA: XBRL DOCUMENT

Related Parties Transactions	9 Months Ended
Related Parties Transactions	Nov. 30, 2017
Related Parties Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	NOTE 5 – RELATED PARTIES TRANSACTIONS On January 24, 2017 the Company entered into a Debt Refinancing Agreement with Mr. Warren Breslow, who served as a Director of the Company from 2006 to 2017. Mr. Breslow resigned his position on our board in March 2017. Pursuant to this agreement, both Mr. Breslow and the Company acknowledged that total debt owed to Mr. Breslow and his affiliates was $23,872,614 including $8,890,574 of accrued interest. Mr. Breslow agreed to cancel and forgive all interest due, waive any past events of default and sign a new, five-year unsecured convertible note, in the amount of $14,982,041. This new note bears no interest through the sooner of (i) January 15, 2018 or (ii) the fifth business day following a shareholder meeting, and 5% per annum thereafter. This new note also provides various default provisions. The refinancing agreement further provides that $11,982,041 of Mr. Breslow’s new note will be converted into 7,403,705 shares of common stock upon stockholder approval of a 1-for-7 reverse stock split within eighteen months of entering into that agreement; the remaining balance may thereafter be converted at any time. In the absence of stockholder approval of a 1-for-7 reverse stock split within eighteen months, the refinancing agreement will become null and void. The Company has elected to continue to accrue interest on this agreement until such time as the 1-for-7 reverse stock split has been approved. The stockholders approved the reverse split at the Company’s stockholder meeting on January 11, 2018. At November 30, 2017, the balance in Notes Payable and accrued interest-related party, current, includes $14,982,041 of unsecured notes payable plus accrued interest of $10,010,053 to Mr. Breslow, a member of our Board of Directors, payable on demand, bearing interest at a rate of 10% per annum. The balance was $14,982,041 plus accrued interest of $8,890,574 as of February 28, 2017. During the periods ended November 30, 2017 and November 30, 2016, interest amounting to $1,119,480 and $993,647 respectively, was incurred on these notes. Related Parties Transactions also includes $82,000 of unsecured notes payable plus accrued interest of $35,268 and $29,141 to our CEO pursuant to a demand note entered into on April 5, 2014 and an unsecured note payable to Mr. Kopple, another member of our Board of Directors in the total amount of $3,029,930 and $3,587,322 plus accrued interest of $2,040,533 and $2,098,616 pursuant to 10% demand note payable as of November 30, 2017 and February 28, 2017, respectively. At November 30, 2017, the balance in Convertible note payable and accrued interest-related party, long term, includes $2,000,000 of secured convertible notes payable plus accrued interest of $1,145,258 to Mr. Kopple.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Commitments	9 Months Ended
Commitments	Nov. 30, 2017
Commitments [Abstract]
COMMITMENTS	NOTE 7 – COMMITMENTS Leases Our facilities consist of approximately 20,000 rented square feet in Stanton, California. The Stanton facility is currently being used for small quantity assembly and testing using components that are produced by various suppliers as well as for general offices, engineering and warehousing. The rent for the Stanton facility is $10,000 per month. The facility is not sufficient for our near term anticipated needs and the Company is actively looking for a new facility. The Company arrangements for the Stanton facility are on a month per month rent. Joint Venture On January 27, 2017, the Company entered into a joint venture (JV) agreement with a Chinese company to manufacture market and distribute certain mobile power products based on Aura’s patented technology solely for the Peoples Republic of China territories. The JV is owned 49% by the Company and 51% by the Chinese company. The Company has contributed $250,000 and a license to specific technology and the Chinese company is required to contribute $9,750,000. In addition, the Chinese company will invest $2,000,000 in Aura at $0.20 per share for a total of 10,000,000 shares of common stock. Additionally, the Chinese company will purchase a minimum of $1,250,000 of product supported by letters of credit for distribution until the joint venture factory is built, equipped, and staffed. In order to assure proper training of joint venture personnel, Aura has also committed to supply instructional personnel for six months at no cost other than reimbursement for travel, room and board. The agreement was subject to the approval of the Chinese Government which was received in April, 2017.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Nov. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS: The Company is presently engaged in a dispute with one of its directors, Robert Kopple, relating to approximately $5.4 million and approximately 22 million warrants which Mr. Kopple claims to be owed to him and his affiliates by the Company. In July 2017, Mr. Kopple filed suit against the Company as well as against current Directors Mr. Gagerman and Mr. Diaz-Verson together with former Directors Mr. Breslow and Mr. Howsmon in connection with these allegations. The Company believes that it has valid defenses in these matters and intends to vigorously defend against these claims.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Accounting Policies (Policies)	9 Months Ended
Accounting Policies (Policies)	Nov. 30, 2017
Accounting Policies [Abstract]
Accounting principles	Accounting principles In the opinion of management, the accompanying balance sheets and related interim statements of income and comprehensive income, and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended February 28, 2017 filed on September 18, 2017 with the U.S. Securities and Exchange Commission.
Estimates	Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this Update supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this Update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU No. 2016-02 on our financial statements. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) that clarifies how to apply revenue recognition guidance related to whether an entity is a principal or an agent. ASU 2016-08 clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to the customer and provides additional guidance about how to apply the control principle when services are provided and when goods or services are combined with other goods or services. The effective date for ASU 2016-08 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. The Company has not yet determined the impact of ASU 2016-08 on its financial statements. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which provides further guidance on identifying performance obligations and improves the operability and understandability of licensing implementation guidance. The effective date for ASU 2016-10 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. In May 2016, the FASB issued ASU 2016-12 “Revenue from Contracts with Customers (Topic 606) - Narrow-Scope Improvements and Practical Expedients,” which amends the guidance on transition, collectability, non-cash consideration, and the presentation of sales and other similar taxes. ASU 2016-12 clarifies that, for a contract to be considered completed at transition, all (or substantially all) of the revenue must have been recognized under legacy GAAP. In addition, ASU 2016-12 clarifies how an entity should evaluate the collectability threshold and when an entity can recognize nonrefundable consideration received as revenue if an arrangement does not meet the standard’s contract criteria. The standard allows for both retrospective and modified retrospective methods of adoption. The Company has not yet determined the impact of ASU 2016-10 on its financial statements. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Statements,” which requires companies to measure credit losses utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2019 (fiscal year 2021 for the Company). The Company has not yet determined the potential effects of the adoption of ASU 2016-13 on its Financial Statements. In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which aims to eliminate diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. ASU 2016-15 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017 (fiscal year 2019 for the Company). The Company has not yet determined the potential effects of the adoption of ASU 2016-15 on its Financial Statements.
Reclassifications	Reclassifications Certain reclassifications have been made to the comparative financial statements to conform to the current period presentation.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

9 Months Ended

Nov. 30, 2017

Notes Payable [Abstract]

Schedule of notes payable

	November 30, 2017		February 28, 2017

Demand notes payable, at 10% and 16%	$	3,413,058	$	3,782,238
Convertible Promissory Note dated August 10, 2012, due August 10, 2017, convertible into shares of our common stock at a price of $0.76 per share. The note carries an interest rate of 7% with interest only payments due on the 10^th of each month with the principal payment due on the maturity date. To-date, the Company has not made any interest payments as set forth in this note.		1,000,000		972,632
Convertible Promissory Note dated October 2, 2012, due October 2, 2017, convertible into shares of our common stock at a price of $0.76 per share. The note carries an interest rate of 7% with interest only payments due on the 2^nd of each month with the principal payment due on the maturity date. To-date, the Company has not made any interest payments as set forth in this note.		500,000		483,951
Senior secured convertible notes dated May 7, 2013, due May 7, 2014, convertible into shares of our common stock at a price of $0.75 per share. The note was not repaid.		2,395,700		2,395,700
Senior secured convertible notes dated June 20, 2013, due June 20, 2014, convertible into shares of our common stock at a price of $0.50 per share. The note was not repaid.		325,000		325,000
Convertible notes dated April 2016 thru November 2017. The notes carry an interest rate of 5% and might be converted into shares of Company’s common stock if the shareholders approve a 1:7’ reverse stock split.		2,409,063		994,700

		10,042,821		8,954,221

Less: Current portion	$	10,042,821	$	8,954,221

Long-term portion	$	-	$	-

XML 27 R17.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

9 Months Ended

Nov. 30, 2017

Accrued Expenses [Abstract]

Schedule of accrued expenses

	November 30, 2017		February 28, 2017

Accrued payroll and related expenses	$	2,781,312	$	3,099,842
Accrued rent		202,036		202,036
Accrued interest		4,073,662		2,562,375
Other		25,000		75,000
Total	$	7,082,010	$	5,939,252

XML 28 R18.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Tables)

9 Months Ended

Nov. 30, 2017

Shareholders' Equity [Abstract]

Schedule of 2006 employee stock option plan

	2006 Plan
	Weighted- Average Exercise Price		Aggregate Intrinsic Value		Number of Options
Outstanding, February 28, 2017		$0.75-$1.00	$	0.00		7,224,000
Cancelled		-		-		-
Granted		-		-		-
Outstanding, November 30, 2017		$0.75-$1.00	$	0.00		7,224,000

Schedule of exercise price options outstanding

Options Outstanding

Exercisable Options

Range of
Exercise
Price

Number

Weighted
Average
Remaining
Life

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life

Number

Weighted
Average
Exercise
Price

$0.75-$1.00

7,224,000

2.25 years

0.79

2.25 years

7,224,000

0.79

Schedule of activity in issued and outstanding warrants

	Number of Shares		Exercise Prices
Outstanding, February 28, 2017		26,454,021		$0.10-$1.00
Granted		1,400,000	$	.20
Exercised		-		-
Cancelled		406,941		1.00
Outstanding, November 30, 2017		27,447,080		$0.10-$1.00

Schedule of exercise prices warrants outstanding

Range of Exercise Prices	Stock Warrants Outstanding		Stock Warrants Exercisable		Weighted- Average Remaining Contractual Life		Weighted- Average Exercise Price of Warrants Outstanding		Weighted- Average Exercise Price of Warrants Exercisable		Intrinsic Value
$0.20		1,400,000		1,400,000		51 months	$	0.20	$	0.20	$	0.00
$0.10-$0.75		18,381,012		18,381,012		41 months	$	0.55	$	0.41	$	0.00
$0.75		1,082,734		1,082,734		39 months	$	0.75	$	0.75	$	0.00
$0.75		1,000,000		1,000,000		29 months	$	0.75	$	0.75	$	0.00
$0.75-$1.00		5,583,334		5,583,334		26 months	$	0.75	$	0.75	$	0.00

		27,447,080		27,447,080

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Going Concern (Details)	3 Months Ended		9 Months Ended
Going Concern (Details)	Nov. 30, 2017 USD ($) ft²	Nov. 30, 2016 USD ($)	Nov. 30, 2017 USD ($) ft²	Nov. 30, 2016 USD ($)
Going Concern (Textual)
Net Loss	$ (1,661,534)	$ (1,073,720)	$ (5,215,524)	$ (3,535,724)
Cash flows from operating activities			$ 2,064,340	$ 752,305
Area of land \| ft²	45,000		45,000

XML 30 R20.htm IDEA: XBRL DOCUMENT

Notes Payable (Details) - USD ($)	Nov. 30, 2017	Feb. 28, 2017
Debt Instrument [Line Items]
Convertible notes payable	$ 10,042,821	$ 8,954,221
Less: Current portion	10,042,821	8,954,221
Long-term portion
Demand notes payable [Member]
Debt Instrument [Line Items]
Demand notes payable	3,413,058	3,782,238
Convertible Promissory Note dated August 10, 2012 [Member]
Debt Instrument [Line Items]
Demand notes payable	1,000,000	972,632
Convertible Promissory Note dated October 2, 2012 [Member]
Debt Instrument [Line Items]
Demand notes payable	500,000	483,951
Senior secured convertible notes dated May 7, 2013 [Member]
Debt Instrument [Line Items]
Demand notes payable	2,395,700	2,395,700
Senior secured convertible notes dated June 20, 2013 [Member]
Debt Instrument [Line Items]
Demand notes payable	325,000	325,000
Convertible notes dated April thru November 2017 [Member]
Debt Instrument [Line Items]
Demand notes payable	$ 2,409,063	$ 994,700

XML 31 R21.htm IDEA: XBRL DOCUMENT

Notes Payable (Parenthetical) (Details)	9 Months Ended
Notes Payable (Parenthetical) (Details)	Nov. 30, 2017 $ / shares
Demand notes payable [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Notes payable interest rate	10.00%
Demand notes payable [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Notes payable interest rate	16.00%
Convertible Promissory Note dated August 10, 2012 [Member]
Debt Instrument [Line Items]
Notes payable interest rate	7.00%
Due date of notes	Aug. 10, 2017
Conversion price per share of notes payable	$ 0.76
Convertible Promissory Note dated October 2, 2012 [Member]
Debt Instrument [Line Items]
Notes payable interest rate	7.00%
Due date of notes	Oct. 02, 2017
Conversion price per share of notes payable	$ 0.76
Senior secured convertible notes dated May 7, 2013 [Member]
Debt Instrument [Line Items]
Due date of notes	May 07, 2014
Conversion price per share of notes payable	$ 0.75
Senior secured convertible notes dated June 20, 2013 [Member]
Debt Instrument [Line Items]
Due date of notes	Jun. 20, 2014
Conversion price per share of notes payable	$ 0.50
Convertible notes dated April thru November 2017 [Member]
Debt Instrument [Line Items]
Notes payable interest rate	5.00%
Due date of notes	Nov. 30, 2017
Reverse stock split	1:7` reverse stock split.

XML 32 R22.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Textual)								1 Months Ended	3 Months Ended	9 Months Ended
Notes Payable (Details Textual)	Feb. 21, 2017 USD ($) shares	Aug. 19, 2013 USD ($) $ / shares shares	Jun. 20, 2013 USD ($) $ / shares shares	May 07, 2013 USD ($) Notes $ / shares shares	Feb. 28, 2013 USD ($) $ / shares	Oct. 02, 2012 USD ($)	Aug. 10, 2012 USD ($)	Jan. 30, 2017	Nov. 30, 2017 USD ($)	Nov. 30, 2017 USD ($)	Nov. 30, 2016 USD ($)
Notes Payable (Textual)
Amortization of debt discount										$ 43,417	$ 192,330
Kenmont Capital Partners [Member] \| Convertible Secured Notes [Member]
Notes Payable (Textual)
Pre conversion debt principal amount				$ 1,000,000
Debt principal amount				$ 1,087,000
Conversion price per share of notes payable \| $ / shares				$ 0.75
Term of warrant				7 years
Amortization of debt discount				$ 342,020
Exercise price per common share under warrant one (in dollars per share) \| $ / shares				$ 0.75
Number of common shares entitlement on exercise of warrant one (in shares) \| shares				1,449,333
Number of notes payable to transferred \| Notes				4
Notes maturity date, term				1 year
LPD Investments, Ltd [Member] \| Convertible Secured Notes [Member]
Notes Payable (Textual)
Pre conversion debt principal amount				$ 550,000
Debt principal amount				$ 558,700
Conversion price per share of notes payable \| $ / shares				$ 0.75
Term of warrant				7 years
Amortization of debt discount				$ 175,793
Exercise price per common share under warrant one (in dollars per share) \| $ / shares				$ 0.75
Number of common shares entitlement on exercise of warrant one (in shares) \| shares				744,933
Number of notes payable to transferred \| Notes				2
Notes maturity date, term				1 year
Holder [Member]
Notes Payable (Textual)
Description of convertible promissory note								The holders of at least 75% of the stock issuable upon conversion of the convertible notes votes to amend the agreement, then such amendments will be binding on all the secured creditors. The five secured creditors signing the amendment total in excess of 95% of the issuable stock upon conversion and, therefore the agreement is binding on all seven of the secured creditors. The amended agreement provides that all accrued and unpaid interest will be added to the principal amount, the amended notes bear interest at the rate of 0% through the sooner of (i) January 15, 2018 or (ii) the fifth business day following a stockholder meeting and 5% per annum thereafter, subject to reduction to comply with applicable law, and mature in 60 months from the effective date of a proposed 1-for-7 reverse stock split (which may only be effected if approved by the stockholders at the next annual meeting of stockholders). Upon certain financings, within five business days following stockholder approval of a 1-for-7 reverse stock split, the Company is obligated to make a payment to the holders of the amended notes in the amount of 20% of the outstanding secured notes. Upon the effectiveness of a proposed 1-for-7 reverse stock split, the remaining 80% balance of the amended notes is converted into shares of the Company's common stock. After the effectiveness of a proposed 1-for-7 reverse stock split, the secured note holders may voluntarily convert the unpaid principal and interest thereon into the Company's common stock at the conversion price of $1.40 per share.
Holder [Member] \| Unsecured Debt [Member]
Notes Payable (Textual)
Notes maturity date, term	5 years
Notes payable interest rate	5.00%
Description of convertible promissory note	Upon stockholder approval of a 1-for-7 reverse stock split
Aggregate unsecured debt	$ 2,237,456
Interest of debt	$ 489,466
Converted shares of common stock \| shares	1,164,555
Holder [Member] \| Convertible Secured Notes [Member]
Notes Payable (Textual)
Debt principal amount			$ 325,000	$ 750,000
Conversion price per share of notes payable \| $ / shares			$ 0.50	$ 0.75
Term of warrant			7 years	7 years
Amortization of debt discount			$ 63,622	$ 235,985
Exercise price per common share under warrant one (in dollars per share) \| $ / shares			$ 0.75	$ 0.75
Number of common shares entitlement on exercise of warrant one (in shares) \| shares			433,334	1,000,000
Notes maturity date, term			1 year	1 year
Holder [Member] \| Board of Directors [Member] \| Unsecured Convertible Notes and Warrants [Member]
Notes Payable (Textual)
Pre conversion debt principal amount		$ 2,500,000
Conversion price per share of notes payable \| $ / shares		$ 0.50
Term of warrant		7 years
Amortization of debt discount		$ 667,118
Exercise price per common share under warrant one (in dollars per share) \| $ / shares		$ 0.75
Number of common shares entitlement on exercise of warrant one (in shares) \| shares		5,000,000
Notes maturity date, term		4 years
Notes payable interest rate		9.50%
Unsecured Convertible Promissory Note [Member]
Notes Payable (Textual)
Pre conversion debt principal amount						$ 500,000	$ 1,000,000
Debt principal amount					$ 1,447,938				$ 615,953	$ 615,953
Conversion price per share of notes payable \| $ / shares					$ 0.76
Amortization of debt discount					$ 402,063	$ 137,583	$ 310,723
Due date of notes					Aug. 10, 2017	Oct. 02, 2017	Aug. 10, 2017
Notes payable interest rate					7.00%	7.00%	7.00%
Description of convertible promissory note				The note due on January 4, 2013 was converted into a portion of the note due June 15, 2013, which carries an interest rate of 12%.		Interest on the unpaid principal amount of this note is payable monthly in arrears on the second day of each calendar month, commencing November 2, 2012. Interest is computed on the actual number of days elapsed over a 360-day year.	Interest on the unpaid principal amount of this note is payable monthly in arrears, on the tenth day of each calendar month, commencing September 10, 2012. Interest is computed on the actual number of days elapsed over a 360-day year.		Pursuant to the terms of these notes, such notes will be converted in their entirety into shares of common stock of the Company at the conversion price of $0.07 per share upon stockholder approval of a 1-for-7 reverse stock split. The warrants entitle the holders to acquire up to an aggregate of 132,000 shares of common stock and have an initial exercise price of $0.20 per share which will be adjusted to $1.40 per share upon stockholder approval of a 1-for-7 reverse stock split. The stockholders approved the reverse stock split at the Company's stockholder meeting on January 11, 2018.
Unsecured Convertible Promissory Note One [Member]
Notes Payable (Textual)
Debt principal amount					$ 1,447,938
Conversion price per share of notes payable \| $ / shares					$ 0.76
Amortization of debt discount					$ 402,063
Due date of notes					Oct. 02, 2017
Notes payable interest rate					7.00%
Unsecured Convertible Promissory Note Two [Member]
Notes Payable (Textual)
Debt principal amount					$ 1,447,938
Conversion price per share of notes payable \| $ / shares					$ 0.76
Amortization of debt discount					$ 402,063
Due date of notes					Jan. 04, 2013
Notes payable interest rate					7.00%

XML 33 R23.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($)	Nov. 30, 2017	Feb. 28, 2017
Accrued Expenses [Abstract]
Accrued payroll and related expenses	$ 2,781,312	$ 3,099,842
Accrued rent	202,036	202,036
Accrued interest	4,073,662	2,562,375
Other	25,000	75,000
Total	$ 7,082,010	$ 5,939,251

XML 34 R24.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Details) - 2006 Plan [Member]	9 Months Ended
Shareholders' Equity (Details) - 2006 Plan [Member]	Nov. 30, 2017 USD ($) $ / shares shares
Weighted - Average Exercise Price
Weighted - Average Exercise Price, Cancelled
Weighted - Average Exercise Price, Granted
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding \| $	$ 0.00
Aggregate Intrinsic Value, Cancelled \| $
Aggregate Intrinsic Value, Granted \| $
Aggregate Intrinsic Value, Outstanding \| $	$ 0.00
Number of Options
Number of Options, Outstanding \| shares	7,224,000
Number of Options, Cancelled \| shares
Number of Options, Granted \| shares
Number of Options, Outstanding \| shares	7,224,000
Minimum [Member]
Weighted - Average Exercise Price
Weighted - Average Exercise Price, Outstanding	$ 0.75
Weighted - Average Exercise Price, Outstanding	0.75
Maximum [Member]
Weighted - Average Exercise Price
Weighted - Average Exercise Price, Outstanding	1.00
Weighted - Average Exercise Price, Outstanding	$ 1.00

XML 35 R25.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Details 1) - 0.75-$1.00 [Member]	9 Months Ended
Shareholders' Equity (Details 1) - 0.75-$1.00 [Member]	Nov. 30, 2017 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Range of Exercise Price, Minimum	$ 0.75
Options Outstanding, Range of Exercise Price, Maximum	$ 1.00
Options Outstanding, Number \| shares	7,224,000
Options Outstanding, Weighted Average Remaining Life	2 years 2 months 30 days
Options Outstanding, Weighted Average Exercise Price	$ 0.79
Exercisable Options, Weighted Average Remaining Life	2 years 2 months 30 days
Exercisable Options, Number \| shares	7,224,000
Exercisable Options, Weighted Average Exercise Price	$ 0.79

XML 36 R26.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Details 2)	9 Months Ended
Shareholders' Equity (Details 2)	Nov. 30, 2017 $ / shares shares
Class of Stock [Line Items]
Number of Shares, Outstanding \| shares	7,224,000
Warrants [Member]
Class of Stock [Line Items]
Number of Shares, Outstanding \| shares	26,454,021
Number of Shares, Granted \| shares	1,400,000
Number of Shares, Exercised \| shares
Number of Shares, Cancelled \| shares	406,941
Number of Shares, Outstanding \| shares	7,224,000
Exercise Prices, Granted	$ 0.20
Exercise Prices, Exercised
Exercise Prices, Cancelled	1.00
Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Exercise Prices, Outstanding	1.00
Exercise Prices, Outstanding	1.00
Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Exercise Prices, Outstanding	0.10
Exercise Prices, Outstanding	$ 0.10

XML 37 R27.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Details 3)	9 Months Ended
Shareholders' Equity (Details 3)	Nov. 30, 2017 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Warrants Outstanding \| shares	7,224,000
Stock Warrants Exercisable \| shares	27,447,080
0.20 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 0.20
Stock Warrants Outstanding \| shares	1,400,000
Stock Warrants Exercisable \| shares	1,400,000
Weighted-Average Remaining Contractual Life	51 months
Weighted-Average Exercise Price of Warrants Outstanding	$ 0.20
Weighted-Average Exercise Price of Warrants Exercisable	0.20
Intrinsic Value	$ 0.00
0.10-$0.75 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Warrants Exercisable \| shares	18,381,012
Weighted-Average Remaining Contractual Life	41 months
Weighted-Average Exercise Price of Warrants Outstanding	$ 0.55
Weighted-Average Exercise Price of Warrants Exercisable	0.41
Intrinsic Value	0.00
0.10-$0.75 [Member] \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices	0.75
0.10-$0.75 [Member] \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices	0.10
0.75 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 0.75
Stock Warrants Outstanding \| shares	1,082,734
Stock Warrants Exercisable \| shares	1,082,734
Weighted-Average Remaining Contractual Life	39 months
Weighted-Average Exercise Price of Warrants Outstanding	$ 0.75
Weighted-Average Exercise Price of Warrants Exercisable	0.75
Intrinsic Value	0.00
0.75 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 0.75
Stock Warrants Outstanding \| shares	1,000,000
Stock Warrants Exercisable \| shares	1,000,000
Weighted-Average Remaining Contractual Life	29 months
Weighted-Average Exercise Price of Warrants Outstanding	$ 0.75
Weighted-Average Exercise Price of Warrants Exercisable	0.75
Intrinsic Value	$ 0.00
0.75-$1.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Warrants Exercisable \| shares	5,583,334
Weighted-Average Remaining Contractual Life	26 months
Weighted-Average Exercise Price of Warrants Outstanding	$ 0.75
Weighted-Average Exercise Price of Warrants Exercisable	0.75
Intrinsic Value	0.00
0.75-$1.00 [Member] \| Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices	1.00
0.75-$1.00 [Member] \| Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 0.75

XML 38 R28.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Details Textual) - USD ($)	9 Months Ended
Shareholders' Equity (Details Textual) - USD ($)	Nov. 30, 2017	Nov. 30, 2016
Shareholders' Equity (Textual)
Common stock shares issued, shares		950,000
Settlement of note payable		$ 150,000
Accrued interest		$ 15,288
Common Stock [Member] \| Settlement Agreement [Member]
Shareholders' Equity (Textual)
Common stock shares issued	$ 665,204
Common stock shares issued, shares	5,116,959
Common Stock [Member] \| Consulting Agreement [Member]
Shareholders' Equity (Textual)
Common stock shares issued	$ 325,000
Common stock shares issued, shares	2,500,000
Common Stock [Member] \| Chinese Joint Venture [Member]
Shareholders' Equity (Textual)
Common stock shares issued	$ 1,000,000
Common stock shares issued, shares	5,000,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

Related Parties Transactions (Details) - USD ($)	1 Months Ended	9 Months Ended
Related Parties Transactions (Details) - USD ($)	Jan. 24, 2017	Nov. 30, 2017	Nov. 30, 2016	Feb. 28, 2017
Related Parties Transactions (Textual)
Unsecured notes payable and accrued interest- related party		$ 30,364,278		$ 29,669,693
Interest expense incurred on unsecured notes payable		$ 1,119,480	$ 993,647
Convertible Secured Notes [Member]
Related Parties Transactions (Textual)
Interest rate		7.00%
Mr. Breslow [Member]
Related Parties Transactions (Textual)
Unsecured notes payable and accrued interest- related party	$ 14,982,041
Debt principal amount	23,872,614
Convertible note payable and accrued interest-related party, net of discount	$ 8,890,574
New debt agreement, term	5 years
Convertible note, amount	$ 11,982,041
Convertible note, shares	7,403,705
Reverse stock split, description	Stockholder approval of a 1-for-7 reverse stock split within eighteen months of entering into that agreement; the remaining balance may thereafter be converted at any time. In the absence of stockholder approval of a 1-for-7 reverse stock split within eighteen months, the refinancing agreement will become null and void. The Company has elected to continue to accrue interest on this agreement until such time as the 1-for-7 reverse stock split has been approved. The stockholders approved the reverse split at the Company's stockholder meeting on January 11, 2018.
Interest rate	5.00%	10.00%
Mr. Breslow [Member] \| Unsecured Debt [Member]
Related Parties Transactions (Textual)
Unsecured notes payable and accrued interest- related party		$ 14,982,041		14,982,041
Mr. Breslow [Member] \| Accrued interest [Member]
Related Parties Transactions (Textual)
Unsecured notes payable and accrued interest- related party		10,010,053		$ 8,890,574
CEO [Member]
Related Parties Transactions (Textual)
Unsecured notes payable and accrued interest- related party		$ 29,141
Related party transaction, date		Apr. 05, 2014
CEO [Member] \| Unsecured Debt [Member]
Related Parties Transactions (Textual)
Unsecured notes payable and accrued interest- related party		$ 82,000
CEO [Member] \| Accrued interest [Member]
Related Parties Transactions (Textual)
Unsecured notes payable and accrued interest- related party		$ 35,268
Mr. Kopple [Member]
Related Parties Transactions (Textual)
Interest rate		10.00%		10.00%
Mr. Kopple [Member] \| Convertible Secured Notes [Member]
Related Parties Transactions (Textual)
Convertible note payable and accrued interest-related party, net of discount		$ 2,000,000
Mr. Kopple [Member] \| Unsecured Debt [Member]
Related Parties Transactions (Textual)
Unsecured notes payable and accrued interest- related party		3,029,930		$ 3,587,322
Mr. Kopple [Member] \| Accrued interest [Member]
Related Parties Transactions (Textual)
Unsecured notes payable and accrued interest- related party		2,040,533		$ 2,098,616
Convertible note payable and accrued interest-related party, net of discount		$ 1,145,258

XML 40 R30.htm IDEA: XBRL DOCUMENT

Commitments (Details)	1 Months Ended	9 Months Ended
Commitments (Details)	Jan. 27, 2017 USD ($) $ / shares shares	Nov. 30, 2017 USD ($) ft²	Nov. 30, 2016 USD ($)
Commitments (Textual)
Area of facility (in square feet) \| ft²		20,000
Rent expense		$ 10,000
Payments for joint venture agreement	$ 250,000	$ 250,000
Joint venture (JV) agreement [Member]
Commitments (Textual)
Joint venture cost method interest rate, percentage	49.00%
Chinese company [Member]
Commitments (Textual)
Payments for joint venture agreement	$ 9,750,000
Sale of equity method investments interest	$ 2,000,000
Shares issue of price per share \| $ / shares	$ 0.20
Ownership percentage in joint venture	51.00%
Sale of common stock \| shares	10,000,000
Common stock purchase minimum amount	$ 1,250,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) $ in Millions	Nov. 30, 2017 USD ($) shares
Subsequent Events (Textual)
Stock warrants outstanding	7,224,000
Robert Kopple [Member]
Subsequent Events (Textual)
Warrants issued value \| $	$ 5.4
Stock warrants outstanding	22,000,000

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 110 165 1 true 37 0 false 6 false false R1.htm 001 - Document - Document and Entity Information Sheet http://aurasystems.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Balance Sheets (Unaudited) Sheet http://aurasystems.com/role/BalanceSheetsUnaudited Balance Sheets (Unaudited) Statements 2 false false R3.htm 003 - Statement - Balance Sheets (Parenthetical) (Unaudited) Sheet http://aurasystems.com/role/BalanceSheetsParentheticalUnaudited Balance Sheets (Parenthetical) (Unaudited) Statements 3 false false R4.htm 004 - Statement - Statements of Operations (Unaudited) Sheet http://aurasystems.com/role/StatementsOfOperationsUnaudited Statements of Operations (Unaudited) Statements 4 false false R5.htm 005 - Statement - Statements of Cash Flows (Unaudited) Sheet http://aurasystems.com/role/StatementsOfCashFlowsUnaudited Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 006 - Statement - Statements of Cash Flows (Parenthetical) (Unaudited) Sheet http://aurasystems.com/role/StatementsOfCashFlowsParentheticalUnaudited Statements of Cash Flows (Parenthetical) (Unaudited) Statements 6 false false R7.htm 007 - Disclosure - Accounting Policies Sheet http://aurasystems.com/role/AccountingPolicies Accounting Policies Notes 7 false false R8.htm 008 - Disclosure - Going Concern Sheet http://aurasystems.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 009 - Disclosure - Notes Payable Notes http://aurasystems.com/role/NotesPayable Notes Payable Notes 9 false false R10.htm 010 - Disclosure - Accrued Expenses Sheet http://aurasystems.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 011 - Disclosure - Shareholders' Equity Sheet http://aurasystems.com/role/ShareholdersEquity Shareholders' Equity Notes 11 false false R12.htm 012 - Disclosure - Related Parties Transactions Sheet http://aurasystems.com/role/Relatedpartiestransactions Related Parties Transactions Notes 12 false false R13.htm 013 - Disclosure - Commitments Sheet http://aurasystems.com/role/Commitments Commitments Notes 13 false false R14.htm 014 - Disclosure - Subsequent Events Sheet http://aurasystems.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 015 - Disclosure - Accounting Policies (Policies) Sheet http://aurasystems.com/role/AccountingPoliciesPolicies Accounting Policies (Policies) Policies http://aurasystems.com/role/AccountingPolicies 15 false false R16.htm 016 - Disclosure - Notes Payable (Tables) Notes http://aurasystems.com/role/NotesPayableTables Notes Payable (Tables) Tables http://aurasystems.com/role/NotesPayable 16 false false R17.htm 017 - Disclosure - Accrued Expenses (Tables) Sheet http://aurasystems.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://aurasystems.com/role/AccruedExpenses 17 false false R18.htm 018 - Disclosure - Shareholders' Equity (Tables) Sheet http://aurasystems.com/role/ShareholdersEquitytables Shareholders' Equity (Tables) Tables http://aurasystems.com/role/ShareholdersEquity 18 false false R19.htm 019 - Disclosure - Going Concern (Details) Sheet http://aurasystems.com/role/GoingConcernDetails Going Concern (Details) Details http://aurasystems.com/role/GoingConcern 19 false false R20.htm 020 - Disclosure - Notes Payable (Details) Notes http://aurasystems.com/role/NotesPayableDetails Notes Payable (Details) Details http://aurasystems.com/role/NotesPayableTables 20 false false R21.htm 021 - Disclosure - Notes Payable (Parenthetical) (Details) Notes http://aurasystems.com/role/NotesPayableParentheticalDetails Notes Payable (Parenthetical) (Details) Details http://aurasystems.com/role/NotesPayableTables 21 false false R22.htm 022 - Disclosure - Notes Payable (Details Textual) Notes http://aurasystems.com/role/NotesPayableDetailsTextual Notes Payable (Details Textual) Details http://aurasystems.com/role/NotesPayableTables 22 false false R23.htm 023 - Disclosure - Accrued Expenses (Details) Sheet http://aurasystems.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://aurasystems.com/role/AccruedExpensesTables 23 false false R24.htm 024 - Disclosure - Shareholders' Equity (Details) Sheet http://aurasystems.com/role/ShareholdersEquityDetails Shareholders' Equity (Details) Details http://aurasystems.com/role/ShareholdersEquitytables 24 false false R25.htm 025 - Disclosure - Shareholders' Equity (Details 1) Sheet http://aurasystems.com/role/ShareholdersEquityDetails1 Shareholders' Equity (Details 1) Details http://aurasystems.com/role/ShareholdersEquitytables 25 false false R26.htm 026 - Disclosure - Shareholders' Equity (Details 2) Sheet http://aurasystems.com/role/ShareholdersEquityDetails2 Shareholders' Equity (Details 2) Details http://aurasystems.com/role/ShareholdersEquitytables 26 false false R27.htm 027 - Disclosure - Shareholders' Equity (Details 3) Sheet http://aurasystems.com/role/ShareholdersEquityDetails3 Shareholders' Equity (Details 3) Details http://aurasystems.com/role/ShareholdersEquitytables 27 false false R28.htm 028 - Disclosure - Shareholders' Equity (Details Textual) Sheet http://aurasystems.com/role/ShareholdersEquityDetailsTextual Shareholders' Equity (Details Textual) Details http://aurasystems.com/role/ShareholdersEquitytables 28 false false R29.htm 029 - Disclosure - Related Parties Transactions (Details) Sheet http://aurasystems.com/role/RelatedPartiesTransactionsDetails Related Parties Transactions (Details) Details http://aurasystems.com/role/Relatedpartiestransactions 29 false false R30.htm 030 - Disclosure - Commitments (Details) Sheet http://aurasystems.com/role/CommitmentsDetails Commitments (Details) Details http://aurasystems.com/role/Commitments 30 false false R31.htm 031 - Disclosure - Subsequent Events (Details) Sheet http://aurasystems.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://aurasystems.com/role/SubsequentEvents 31 false false All Reports Book All Reports ausi-20171130.xml ausi-20171130.xsd ausi-20171130_cal.xml ausi-20171130_def.xml ausi-20171130_lab.xml ausi-20171130_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 48 0001213900-18-000698-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-18-000698-xbrl.zip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